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brain long after acute infection has resolved, typically in the absence of clinical signs of CNS disease. In
many of these infections, (including measles virus (MV), West Nile virus, sindbis virus, rabies virus, and
influenza virus), detection of viral protein or RNAs within the CNS long after the acute phase did not
correlate with recovery of infectious virus in infected animals. This led many to consider these residual
RNAs as inert viral remnants in neurons that had survived both viral infection and the antiviral host
response. In this dissertation, I demonstrate that long-term viral persistence following infection with a
neurotropic RNA virus can be reactivated, and that such recrudescence leads to a novel neuropathogenic
outcome. In these studies, I characterized the persistence of MV in neurons of the CNS in
immunocompetent mice and demonstrate that reactivation of viral transcription and protein synthesis is
associated with a loss of adaptive immunity and the onset of severe CNS disease and motor dysfunction
in mice that had presumably cleared the acute infection. The cerebellum/brain stem is the primary site of
long-term maintenance of viral RNA, and loss of cell mediated viral control induces gait and motor
problems consistent with cerebellar ataxia. Finally, using primary neuronal cultures I characterized the
role of BST2 during neuronal viral infection and demonstrate, opposite to its well-characterized
contributions in restricting viral particle release, that neuronal BST2 promotes viral spread. Together,
these results show that persistent viral RNAs in the CNS are not inert, but can result in pathogenic host
consequences distinct from those seen during an acute viral infection. Further, my findings underscore
the cell-type specific differences of viral infection on ISG functions and immunity, highlighting the
ramifications of such viral control mechanisms and their ability to promote the maintenance of viruses in
the CNS that can ultimately lead to host pathogenesis.
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ABSTRACT
NEURONAL SURVIVAL FOLLOWING RNA VIRUS INFECTION FACILITATES VIRAL
PERSISTENCE, REACTIVATION, AND PATHOGENESIS
Katelyn D. Miller
Glenn F. Rall, Ph.D.

Many RNA viruses, following entry into the central nervous system (CNS),
remain detectable within the brain long after acute infection has resolved, typically in the
absence of clinical signs of CNS disease. In many of these infections, (including
measles virus (MV), West Nile virus, sindbis virus, rabies virus, and influenza virus),
detection of viral protein or RNAs within the CNS long after the acute phase did not
correlate with recovery of infectious virus in infected animals. This led many to consider
these residual RNAs as inert viral remnants in neurons that had survived both viral
infection and the antiviral host response. In this dissertation, I demonstrate that longterm viral persistence following infection with a neurotropic RNA virus can be
reactivated, and that such recrudescence leads to a novel neuropathogenic outcome. In
these studies, I characterized the persistence of MV in neurons of the CNS in
immunocompetent mice and demonstrate that reactivation of viral transcription and
protein synthesis is associated with a loss of adaptive immunity and the onset of severe
CNS disease and motor dysfunction in mice that had presumably cleared the acute
infection. The cerebellum/brain stem is the primary site of long-term maintenance of viral
RNA, and loss of cell mediated viral control induces gait and motor problems consistent
with cerebellar ataxia. Finally, using primary neuronal cultures I characterized the role of
BST2 during neuronal viral infection and demonstrate, opposite to its well-characterized
vii

contributions in restricting viral particle release, that neuronal BST2 promotes viral
spread. Together, these results show that persistent viral RNAs in the CNS are not inert,
but can result in pathogenic host consequences distinct from those seen during an acute
viral infection. Further, my findings underscore the cell-type specific differences of viral
infection on ISG functions and immunity, highlighting the ramifications of such viral
control mechanisms and their ability to promote the maintenance of viruses in the CNS
that can ultimately lead to host pathogenesis.
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CHAPTER 1: Keeping it in check: chronic viral infection and
antiviral immunity in the brain

This chapter is adapted from
Miller KD, Schnell MJ, Rall GF. Keeping it in check: chronic viral infection and antiviral
immunity in the brain. Nature Reviews Neuroscience. November 2016:1-13.
doi:10.1038/nrn.2016.140.

We gratefully acknowledge Dr. Christine Matullo and the rest of the Rall lab for their
contributions in discussing this manuscript as well as our funding sources from the
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I. Preface
It is becoming clear that the manner by which the immune response resolves or
contains infection by a pathogen varies based on the affected tissue. Unlike many
peripheral cell types, central nervous system (CNS) neurons are generally nonrenewable. Thus, cytolytic and inflammatory strategies that are effective in controlling
infections in the periphery could be damaging if deployed in the CNS. Perhaps for this
reason, the immune response to some CNS viral infections favors maintenance of
neuronal integrity and non-neurolytic viral control. This modified immune response —
when combined with the unique anatomy and physiology of the CNS — provides an
ideal environment for the maintenance of viral genomes, including those of RNA viruses.
It is therefore possible that such viruses can reactivate long after initial viral exposure,
contributing to CNS disease. My thesis work uses a mouse model of neuroviral infection
to provide mechanistic insights into the maintenance of RNA viral genomes within the
CNS, and how reactivation of viral replication can result in novel diseases long after the
primary infection.
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II. Introduction
An oversimplification that is promoted in much of the scientific literature is that
extracellular, receptor-binding ligands — including viruses, cytokines, and interferons
(IFNs) — transduce invariant signaling pathways, independent of the activated cell type.
Such generalizations limit our ability to fully appreciate the complexity and diversity of
the cellular response to pathogens and potent pathogen-fighting proteins. There are also
clinical ramifications of this myopic view: for example, ignoring the possibility that a
particular cell population may behave uniquely upon cytokine encounter could limit drug
efficacy or hinder the development of therapeutics. Here, I discuss some recently
defined neuron-specific immune responses that broaden our view of how CNS
infections, especially those caused by RNA viruses, are controlled.
Intuitively, the notion that neurons differ immunologically from other cell types
makes sense: we cannot tolerate the loss of these generally nonrenewable cells as we
can the lysis of more easily replaced epithelial cells. For example, herpes simplex virus
(HSV) infection of epithelial cells results in massive immune- and virus-mediated cell
death (Paludan et al. 2011; Jones et al. 2003; Braaten et al. 2005); however, lost cells
are readily replaced, as observed in the healing that follows a cold sore. If lysis of
irreplaceable neurons occurred in the same manner, neural circuits could become
compromised, and, depending on the magnitude of damage, could permanently impair
the host. Thus, the immune response to a viral challenge must be tailored to promote
survival of infected neurons while destroying infected epithelial or endothelial cells.
However, such neuronal sparing might result in long-term consequences that are
spatially or temporally separated from acute infection.
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In this introductory chapter, I will integrate insights from the fields of virology,
neurobiology and immunology to provide an overview of how both RNA viruses and DNA
viruses access the restricted environment of the CNS, and how the host contends with
such infections. I will particularly focus on a developing literature that elucidates cellspecific immunity and the consequences of non-lytic viral clearance within the brain.
These unique attributes of immune-mediated viral control in the brain may set the stage
for persistence of viruses in neurons, rather than sterile clearance, the focus of my
research. Thus, this chapter then focuses on unique observations gained from a model
of measles virus infection of the CNS, which are particularly pertinent to the studies
presented throughout my dissertation. I conclude with a forward-looking hypothesis: that
non-lytic clearance of neuronal infections may allow for persistence of RNA viruses that
induce pathogenesis long after primary exposure.

III. Viral Entry and Spread into the CNS
Viral entry

The brain is shielded from external threats at both macro- and microscopic
levels: it is encased in bone to prevent physical injury and separated from peripheral
tissues and blood via highly specialized barriers. Although such characteristics may limit
infections of CNS-resident cells, these barriers can be breached. Three major routes of
viral entry into the brain have been identified: direct infection of the cells that comprise
the blood–brain barrier (BBB) and blood–cerebrospinal fluid (BCSF) barrier (with
consequent release of viral particles into the parenchyma), infection of cells that are able
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to cross these barriers, and trans-neuronal migration across synapses from the
peripheral nervous system (PNS) into the CNS (Figure 1.1 and 1.2).
Within the CNS, the BBB and BCSF barriers restrict the migration and diffusion
of cells, pathogens, antibodies, and macromolecules into the brain parenchyma.
Neurotropic RNA viruses, including poliovirus (PV), measles virus (MV), and some
flaviviruses, can circumvent these barriers by directly infecting the tightly associated
endothelial or epithelial cells that comprise them (Koyuncu et al. 2013). Viral particles
can then be released from the basolateral membrane into the parenchyma. For example,
following MV infection of human brain microvascular endothelial cells (HBMEC), release
of viral particles occurs from both the apical and basolateral HBMEC membranes,
without disrupting cell polarity or barrier integrity, allowing MV to spread into the
parenchyma (Dittmar et al. 2008). Alternatively, barrier integrity may be compromised
when the tight junctions between these cells loosen due to inflammation and cytokine
exposure, allowing free viral particles to diffuse directly from the blood or CSF into the
brain. For example, peripheral West Nile virus (WNV) infection acts through the
engagement of Toll-like receptor 3 (TLR3) to induce the synthesis of cytokines —
including tumor necrosis factor-alpha (TNFα) — by circulating antigen presenting cells
(T. Wang et al. 2004). In turn, TNFα reduces BBB integrity by loosening tight junctions
(Libbey & Fujinami 2014), allowing for WNV migration through the less-restrictive BBB.
In reality, immune modulation of barrier integrity is not as simple as this description
implies. The balance of different cytokines can determine the extent to which the BBB is
perturbed or stabilized. For example, IFNs, which are also produced in infected hosts,
help to keep the barrier intact (Daniels et al. 2014); thus, the relative type and ratios of
cytokines synthesized in response to various infections will differentially affect barrier
integrity (Daniels & Klein 2015).
5

Viruses may also passively access resident CNS cells by infecting lymphocytes
or monocytes that can be transported across a cellular barrier. This strategy is often
referred to as the “Trojan horse” approach, because viral particles are released once the
leukocyte gains access to the parenchyma. A classic example of this mode of invasion is
human immunodeficiency virus type 1 (HIV-1), in which CD16+ monocytes, permissive
for HIV-1, traffic across the BBB and release virions that can then infect CNS resident
microglia (McGavern & Kang 2011; Kramer-Hämmerle et al. 2005).
A third mode of CNS entry is trans-neuronal migration, a strategy adopted by
pseudorabies virus (PRV), rabies virus (RV), and many herpesviruses. Intracellular
trafficking in PNS neurons, which is necessary to shuttle cellular components to and
from the synapse, can be commandeered to facilitate viral travel within and among
synaptically-connected neurons. The best-characterized examples of this type of spread
are members of the herpesviruses, including herpes simplex virus type 1 (HSV-1), and
the closely related PRV (Koyuncu et al. 2013; Kramer & Enquist 2013). Following
infection of epithelial cells in the oral mucosa, HSV-1 spreads to sensory and autonomic
ganglia, establishing lifelong latency. Reactivation of virus from latency — due to
decreases in immune monitoring, other infections, or stress — leads to an active
infection in PNS neurons, in which viral membrane proteins (including US9, glycoprotein
E (gE) and glycoprotein I (gI)) can direct movement of newly replicated viral particles
from neurons to the epithelium, establishing a new lytic infection (Howard et al. 2012).
During transport, viral components are shuttled along axons via microtubule tracks and
in association with their dynein and kinesin motors (Kramer et al. 2012; Zaichick et al.
2013). Beyond the value of these studies to understand how neurotropic viruses are
propagated, viruses which spread across synapses (which also include RV and MV)
have provided a valuable method to trace neural circuits in vivo (Granstedt et al. 2013;
6

Hagendorf & Conzelmann 2015) using recombinant viruses encoding fluorescent
proteins. These unique virological tools may also inform the development of strategies to
deliver therapeutic payloads from the periphery to the CNS.

Figure 1.1: Viral entry into the CNS. Three modes of viral entry into the brain are shown.
Viruses may directly infect the cells comprising the blood–brain barrier (BBB), followed
by release into the parenchymal space (left panel). Alternatively, viruses may diffuse
across permeable regions of the BBB (middle panel). Of note, BBB permeability can be
influenced by cytokines, such as tumor necrosis factor (TNF) and various interferons
(IFNβ, IFNγ and IFNλ), which can loosen or reinforce the barrier integrity. In the ‘Trojan
horse’ approach (right panel), infected lymphocytes or monocytes (including
macrophages) traffic across the BBB or blood–cerebrospinal fluid barrier, releasing virus
once in the brain parenchyma. Miller KD, Schnell MJ, Rall GF. Keeping it in check:
chronic viral infection and antiviral immunity in the brain. Nature Reviews Neuroscience.
November 2016:1-13.
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Figure 1.2: Viral spread in neurons.

Trans-synaptic spread of viral particles involves the transport of viral genomes and
associated proteins via microtubules and molecular motors. The left panel shows the
movement of rabies virus (RV) from the muscle, across the neuromuscular junction, and
the dynein-mediated retrograde transport of this virus into the CNS. In the right panel,
the transport of viruses (including herpes simplex virus (HSV), varicella zoster virus
(VZV) and pseudorabies virus (PRV)) occurs across the epithelial or endothelial–neuron
junction. In these neurons, retrograde transport brings the virus to the neuronal soma,
and anterograde transport delivers the virus to the peripheral nervous system (PNS)–
CNS synaptic junction. IFNAR, IFN α/β receptor; IFNGR, IFNγ receptor; HIV-1, human
immunodeficiency virus type 1; MV, measles virus; PV, poliovirus; TNFR, TNF receptor;
WNV, West Nile virus. Miller KD, Schnell MJ, Rall GF. Keeping it in check: chronic viral
infection and antiviral immunity in the brain. Nature Reviews Neuroscience. November
2016:1-13.
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Viral spread
Once a virus has infected a neuron, there are two primary modes of subsequent
spread to other cells: release of infectious viral particles that can infect distant
permissive cells, or transfer of viral nucleic acid, subviral particles, or infectious virions
between an infected and uninfected cell that are in direct contact. The former
mechanism requires release of viral particles through the neuronal membrane (chiefly
via budding out of the infected cell), whereas the latter is primarily dependent on viral
proteins that mimic or co-opt cellular processes to direct insertion of viral fusion proteins
into a host cell membrane or to direct the spread of viral capsids, as seen with HSV
(Kramer & Enquist 2013). Both modes of viral spread occur in neurons; however, in
many instances, viral transfer to adjacent neurons happens in the absence of syncytia
formation, and little or no extracellular infectious virus can be detected, suggesting that
neurons facilitate a distinct mode of spread for many viruses (Koyuncu et al. 2013).
Interestingly, trans-synaptic spread of MV within primary mouse hippocampal neurons
occurs independently of known MV receptors, which are critical for syncytia formation in
non-neuronal cells (Lawrence et al. 2000; Makhortova et al. 2007). The paucity of viral
particles in the extracellular space may protect the neuron from plasma membrane
damage via budding, and facilitate viral evasion of antibody detection. Although many
neurotropic infections spread by direct contact at the pre- and post-synaptic junction,
alternative modes of transport may also be used (Chapter 3 and Appendix). For
example, although RV primarily spreads trans-synaptically in a retrograde manner, an
electron microscopy study showed the presence of viral particles in the extracellular
neuronal space, accompanied by direct neuronal budding (Iwasaki et al. 1975).

9

Syncytia formation and trans-synaptic spread
Viruses gain entry into permissive cells through an interaction between virallyencoded glycoproteins, expressed on the outer surface of the virus particle, and cellular
receptors. Entry can be achieved through endocytosis into vesicles or via membrane
fusion (Zhong et al. 2013). For fusogenic viruses, exit from the cell occurs either through
the budding of virus particles through the plasma membrane or by fusion of an infected
cell with an adjacent, uninfected cell (Zhong et al. 2013). The latter process results in the
formation of multinucleated cells, or syncytia. The formation of syncytia may support
further viral production but irrevocably leads to the death of these fused cells. Similarly,
release of infectious particles by budding often leads to infected cell death (Watanabe et
al. 2015).
However, viruses that are considered cytopathic in renewable cell types —
including MV, RV and PRV — can switch to a non-productive, non-syncytia forming
mode of spread when infecting neurons, promoting neuronal survival (Lawrence et al.
2000; Makhortova et al. 2007; Kramer & Enquist 2013; Taylor et al. 2012; Lancaster &
Pfeiffer 2010). Often, this is correlated with the absence of detectable extracellular viral
particles. Spread of these viruses within neurons is primarily trans-synaptic, although the
neuronal processes that enable a switch from viral budding and syncytia formation to
non-cytolytic, trans-synaptic spread are not yet defined.
At least two possibilities might explain viral movement across the synapse. In
one scenario, spread of viral particles between neurons requires ligand-receptor
interactions, similar to infection in non-neuronal cells. Directed transport to the synapse
and focal fusion at the synaptic cleft might be required for a virus to migrate across the
synapse: thus, the process that occurs in non-neuronal cells might also be operative in
10

neurons. Trans-synaptic spread might require the same cellular and viral proteins that
allow for fusion of non-neuronal cells, or may be unique to the pre-post synaptic
interface (Appendix). For example, in MV neuronal infection, expression of the primary
receptors that are utilized in non-neuronal cell infection are not required; however, a
fusion event still is critical for spread to occur, perhaps by forming a “pore” through which
the viral ribonucleic acid is transported (Sattentau 2008).
Alternatively, the close approximation between the pre- and post-synaptic
membrane, coupled with the unique attributes of the synaptic junction, may allow for the
passive transport of viruses that have trafficked or assembled there (discussed in more
detail in the appendix to this dissertation). The release of neurotransmitters and uptake
of their receptors make the synaptic interface particularly fluid, which may make it
uniquely able to support receptor-independent trafficking.

Defining long-lasting neuronal infections
One outcome of viral neuroinvasion is that the viral genome, proteins, and/or
complete virus particles may remain in the brain long after initial exposure. To describe
the myriad ways by which viruses establish enduring interactions with host neurons,
numerous descriptors have been employed, including “prolonged”, “persistent”, “latent”,
“smoldering”, “quiescent” and “chronic” (Wherry & Ahmed 2004; Oldstone 2009;
Koyuncu et al. 2013); however, their use is not consistent. Variables including detection
threshold, target organs, and cell-specific influences on the viral life cycle collectively
contribute to the challenge of establishing an agreed-upon nomenclature. Moreover,
some viruses can reactivate to cause the same disease as the acute infection (such as
herpes simplex), while others manifest differently upon reactivation (such as varicella
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zoster virus (VZV), which causes chicken pox as a primary infection, but typically causes
shingles upon reactivation). Others result in pathogenesis only after protracted infection
(such as tumor-causing viruses).
To provide some clarity to this ambiguous list of descriptors, I propose three
classifications. Latent infections are defined as those in which the virus establishes a
non-lytic state during which host-to-host transmission is not possible unless the virus
reactivates to produce infectious virions. Chronic transmissible infections are
characterized by the continuous production of infectious progeny, and their ability to be
transferred to new hosts. Chronic non-transmissible infections are those in which
consistent detection of viral nucleic acid over extended periods of time is observed, but
in which transmission to new hosts does not occur.
Latency is most frequently attributed to herpesvirus infections, such as HSV-1,
HSV-2 and VZV. After initial infection of epithelial cells, these viruses become non-lytic
within PNS neurons and viral nucleic acid is maintained in a heterochrominated
episomal state with negligible transcription (Kramer & Enquist 2013). A small number of
viral transcripts are synthesized during latency and are termed latency-associated
transcripts (LATs). These RNA species do not encode functional proteins, but are
thought to prevent neuronal apoptosis and to disrupt both innate and adaptive immune
signaling, through mechanisms that include inhibition of caspase activity and granzyme
B-mediated killing (Kinchington et al. 2012; Jiang et al. 2011). VZV also produces
various proteins, including ORF63, that prevent neuronal apoptosis (Kinchington et al.
2012). The term “latent” accurately conveys the status of these viruses: hidden,
incapable of transmission, but able to fully reactivate, spread, and be transmitted to a
new host. Another type of latency, which is not typically seen in neurons, occurs after
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viral nucleic acid is reverse transcribed from RNA to DNA and then integrated into the
host genome. This process is unique to the retroviruses, such as HIV-1 (Mohammadi et
al. 2015). In this type of latency, integrated viral genomic DNA becomes
indistinguishable from host DNA, and viral genes can be epigenetically silenced or
activated throughout the cell’s lifetime and passed on to daughter cells.
In a chronic transmissible infection, infectious virus can be continuously
recovered from the host and can be disseminated to new hosts, as in hepatitis B and C.
A well-characterized mouse model of a chronic transmissible CNS infection is
lymphocytic choriomeningitis virus (LCMV). LCMV infection of newborn mice leads to a
noncytopathic chronic infection in almost every tissue. Infectious LCMV particles can be
recovered from multiple organs throughout life and can be shed in the feces or
transmitted vertically to offspring (Oldstone 2009; Oldstone 2006; Traub 1936). Although
most strains of mice survive LCMV infection with no overt pathogenic consequences,
some studies reported learning and memory deficits in these chronically infected animals
(Brot et al. 1997), underscoring the potentially subtle effects of long-term infection on
CNS function.
Chronic non-transmissible infections are also characterized by sustained viral
replication or consistent detection of viral nucleic acid over extended periods of time, but
in the absence of further host dissemination. One example may be rare cases of CNS
infection with measles. Acute infection can, in some instances, lead to the development
of neuropathogenic diseases, including subacute sclerosing panencephalitis (SSPE) and
measles inclusion body encephalitis (MIBE). These uncommon neurological diseases
often present months to years after viral exposure, and are characterized either by
negligible viral replication or persistence of replication-competent nucleic acid in the
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CNS (Norrby & Kristensson 1997; Gutierrez et al. 2010; Griffin 2014). In both SSPE and
MIBE, no viral dissemination to uninfected hosts has been reported. Determining
whether the state of the virus that causes these sequelae is “latent” or “chronic nontransmissible” is difficult, due both to the small number of clinical specimens available,
and a lack of small animal models that mimic SSPE disease (Griffin et al. 2012; Hayashi
et al. 2002; Gutierrez et al. 2010). In humans, it may be that neurological symptoms
appear only once viral replication reaches a critical threshold or that the virus has
infected a key site within the brain, exceeding the host’s capacity to control the infection.
Alternatively, non-replicating MV genomes may be maintained for prolonged periods, to
be reactivated later. Either way, the MV genome remains intact, in some form, long after
control of the acute infection is achieved, in the absence of further viral dissemination.
A final point of clarification: not all neurotropic infections lead to long-lasting
associations. Some, such as reovirus, can induce neuronal apoptosis via induction of
pro-apoptotic proteins such as BAX (Clarke et al. 2009; Berens & Tyler 2011). Why
some infections lead to neuronal suicide while others lead to a long (potentially unhappy)
marriage is a major focus in the field of neurovirology: answering this question may lead
to the discovery of virus-specific therapies to prevent or minimize infection-triggered
neuropathology.
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IV. Immune Clearance of Neuronal Infection
The various permutations of neurotropic viral infections pose unique challenges
for the host, including how to detect antigens within the CNS, how to enable T
lymphocytes to engage with neurons that express negligible levels of proteins typically
present on target cells, and how to mitigate the risks of neuroinflammation and
widespread loss of generally nonrenewable neurons.

Type I interferon signaling

The early response to an infection begins with engagement of pathogenic motifs
by pattern recognition receptors (PRRs), which are expressed on (or in) virtually all cells.
The binding of these receptors to conserved motifs, such as double-stranded RNA,
lipopolysaccharides, or glycoproteins, propagates signals that culminate in the
production of type I IFNs, chiefly IFNα and IFNβ. These IFNs are secreted from the
infected cell, and act in both a paracrine and autocrine fashion by binding to the type I
IFN receptor (IFNAR), a heterotetramer with phosphorylatable cytoplasmic domains.
This engagement leads to the phosphorylation of tyrosine kinases (including Janusassociated kinases) and the receptor itself, and is followed by tyrosine phosphorylation
of cytoplasmic signal transducer and activator of transcription 1 (STAT1) and STAT2,
which are usually abundant but inactive within the cytoplasm. Activated STAT1–STAT2
heterodimers couple with interferon regulatory factor 9 (IRF9) to form the complex
ISGF3, which translocates to the nucleus to bind IFN stimulated response elements
(ISRE) within the promoters of IFN stimulated genes (ISGs). These genes encode
proteins that eliminate infected cells or aid in viral clearance. Type I IFN also binds to
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adjacent, uninfected cells to shield them from infection. Although this pathway is
operative in many cells, alternative IFN-triggered pathways that limit viral spread, but do
not depend on induction of the “usual suspect” ISGs can be induced in some cell types,
including neurons (Goodbourn et al. 2000).
Neurons also secrete type I IFNs, which can act in an autocrine or paracrine
manner on neurons or neighboring parenchymal cell types (Delhaye et al. 2006). RV,
which infects muscle cells and peripheral neurons following a bite from an infected
animal, induces copious IFN early after infection in vivo and in vitro (Faul et al. 2010). By
contrast, IFN-induced STAT phosphorylation in primary hippocampal neurons is
delayed, with maximal activation occurring only after ~24 hours (Rose et al. 2007;
Cavanaugh et al. 2015). Delayed STAT activation coincides with delayed expression of
traditional ISGs (Cavanaugh et al. 2015). The protracted interval between receptor
binding and STAT activation may be due to a greatly reduced basal expression of STAT
in these hippocampal neurons, as compared to other cell types (Rose et al. 2007;
Podolsky et al. 2012; Cavanaugh et al. 2015). Interestingly, lower homeostatic STAT
expression is not unique to neurons, but has also been observed in another nonrenewable cell type, cardiac myocytes (Zurney et al. 2007). Like neurons, cardiac
myocytes have high basal IFNβ expression, which may protect them from infection
(Cavanaugh et al. 2015; Zurney et al. 2007). Perhaps the disparity between expression
of IFNs and the signal transduction molecules that they induce may skew towards
protection from infection, rather than induction of a potentially cytotoxic response.
Surprisingly, synthesis of ISGs can differ within a single neuron: IFN-β induces a
noncanonical, local antiviral response in axons that is not observed in the neuronal soma
(Rosato & Leib 2015; Song et al. 2016). The startling implication of this work is that
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neurons, especially those with long processes as in the PNS, may “compartmentalize”
the response to extracellular immune mediators.
Although much of this introductory chapter focuses on neuronal responses to
infections and antiviral cytokines, it is important to underscore that differential responses
to, and production of, type I IFN have been demonstrated in other parenchymal cell
populations as well, and may influence the neuronal response. For example, when
comparing microglia and oligodendroglia collected after infection with a neurotropic
strain of mouse hepatitis virus (MHV), it was shown that microglia are better producers
of type I IFN and downstream interferon-stimulated gene products (Kapil et al. 2012).
Further studies using MHV have shown that viral tropism is determined after viral entry
events and dependent on downstream type I IFN responses (Zhao et al. 2011, Zhao et
al. 2013). Overall, the fact that different cell types show distinct homeostatic expression
of key signal transducers and their downstream gene targets underscores the cellular
diversity that can follow cytokine engagement.
Perhaps predictably, for many neurotropic RNA viruses, including MV, Theiler’s
murine encephalomyelitis virus (TMEV), Murray Valley encephalitis virus (MVEV), WNV,
and others, experimentally-induced loss of type I interferon signaling results in
pathogenesis, altered viral tropism (generally enhanced neurovirulence), and an inability
to control viral spread both in vivo and in vitro (Paul et al. 2007; Holmgren, Miller,
Cavanaugh & Rall 2015a; Ireland et al. 2007; Cavanaugh et al. 2015; Weber et al. 2014;
Fensterl et al. 2012; Samuel & Diamond 2005; Lobigs 2003; Nayak et al. 2013).
Although most of these studies were performed using type I IFN receptor knockout mice
(IFNAR KO) lacking receptor expression on all cells, selective disruption of neuronal IFN
signaling (using neuron-specific knockouts of IFNAR) also results in death following VSV
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infection (Detje et al. 2009). Moreover, infection of olfactory neurons and mucosa with
either a neurotropic RNA virus (VSV) or a neurotropic DNA virus (cytomegalovirus) leads
to a robust type I IFN response deep within the brain, preventing viral spread and
attendant disease (van den Pol et al. 2014). Thus, infection of cells in direct contact with
the environment (including sensory olfactory neurons) can trigger a long-distance
warning (production of type I IFN) that ultimately limits or precludes viral spread to
remote regions of the brain.

Antigen presentation and generation of CNS immunity

For some time, it was known that the primary cell populations of the adaptive
immune system, T cells and B cells, contributed to viral control within the brain; however,
the apparent absence of a CNS lymphatic drainage system left it unclear how antigens
could exit the parenchyma to promote the activation and proliferation of naïve antigen
specific T cells (Libbey & Fujinami 2014). Recent findings have begun to resolve this
mystery: these include the identification of lymphatic drainage portals from the CNS into
deep cervical lymph nodes and the presence of a fluid gradient that flushes the brain of
extracellular proteins (termed “glymphatics” because of the crucial role of glia in this
process) (Aspelund et al. 2015; Jessen et al. 2015; Louveau et al. 2015). CSF moves
toward the perivascular space, where it is transported into the dense brain parenchyma
via aquaporin 4 water channels expressed on cortical astrocytes. The CSF movement
drives interstitial fluid (ISF) toward perivenous spaces, where it then drains toward the
newly identified meningeal or dura matter lymphatic vessels, and ultimately to the deep
cervical lymph nodes, where T cell activation and proliferation can occur (Aspelund et al.
2015; Louveau et al. 2015; Iliff et al. 2012). These studies illuminate how antigens and
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professional antigen presenting cells can exit the CNS to alert naive T cells in the lymph
nodes.

T cell mediated pathogen clearance

After T cells mature in lymphoid tissues, they enter the bloodstream where they
can interact with adhesion molecules expressed on the surface of blood vessel
endothelia within infected tissues. Mature T cells chiefly engage with selectins (and later,
integrins) on the surface of the BBB or BCSF barrier. The expression of these adhesion
molecules is induced by chemokines produced within the parenchyma by infected
neurons and adjacent glia. This results in migration of T cells across the barrier
(diapedesis). Although it was previously believed that neurons do not express major
histocompatibility complex (MHC) class I molecules (and thus could not be recognized,
at least in the canonical manner, by CD8+ T cells), we now know that some neuronal
populations constitutively synthesize these cell surface proteins and that others can
induce them following injury or infection (Neumann et al. 1995; Neumann et al. 1997;
Cebrián et al. 2014). Even so, most neurons do not express typical levels of class I MHC
antigens under noninflammatory conditions (Joly et al. 1991), and thus T cell effector
functions, including cytokine production, may not be triggered by the infected cell (the
neuron) directly but rather by adjacent class I MHC-expressing cells (usually glia) that
can display antigenic peptides via cross-presentation (Calzascia et al. 2003). Although
cross-presenting glia may not be directly infected, this strategy allows for elaboration of
antiviral processes. Resident CNS cells may not only be invisible to immune cells due to
reduced

expression

of

MHC

recognition

molecules,

but

may

also

express

immunomodulatory molecules, such as programmed death 1 ligand 1 (PD-L1) (Jeon, St
19

Leger, Cherpes, Sheridan & Hendricks 2013a), that downmodulate T effector function.
Remarkably, the class I MHC expression system that is key to T cell recognition likely
has other functions in neurons as well, including neurodevelopment and neuronal
plasticity (Huh et al. 2000; Cebrián et al. 2014; Goddard et al. 2007).
One of the major strategies used by activated T cells to combat neuronal viral
infections is the production of IFNγ. Similar to the type I IFNs, IFNγ transduces a signal
via receptor binding, leading to STAT1 activation and homodimerization. Activated
STAT1 homodimers translocate to the nucleus, bind to gamma activated sequences
(GAS) in the promoters of approximately 100 genes (which overlap with, but are
generally distinct from, the ISGs induced by type I IFNs), promoting their transcription
and translation (Figure 1.3). These gene products, similar to ISG proteins, combat viral
infection or induce apoptosis of the infected cell (Goodbourn et al. 2000).
STAT1 can be activated in neurons after IFNγ exposure, but the kinetics of
induction are markedly slower than those observed in treated mouse embryonic
fibroblasts (MEFs), similar to the delayed response seen following type I IFN exposure
(Rose et al. 2007). In addition, IFNγ induces the transcription of both traditional genes
(that is, those that are typically expressed in response to IFNγ in other cellular
populations) and non-traditional genes in primary hippocampal neurons after exposure
(O'Donnell et al. 2012). This diverse profile of changes in gene expression may affect
the cellular outcome: although IFNγ can induce necroptosis, in neurons the virus is
controlled in a non-cytolytic manner (presumably due to the paucity of STAT1 and nontraditional GAS gene induction) (Burdeinick-Kerr et al. 2009; Patterson, Lawrence, et al.
2002) (Figure 1.3). This is not unique to neurons: IFNγ is also essential for controlling
MHV infection of oligodendrocytes via non-cytolytic pathways (Parra et al. 1999;
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González et al. 2006). How are genes activated when basal levels of available STAT1
are low in resting neurons? Interestingly, the majority of STAT1 KO mice challenged with
a neuron-restricted MV infection survive. By contrast, IFNγ KO mice all show severe
signs of chronic disease, with approximately 50% succumbing to infection (O'Donnell et
al. 2012; Patterson, Lawrence, et al. 2002), suggesting that the requirement for IFNγ is
decoupled from the main transducer through which it signals. This observation led to the
identification of an IFNγ-dependent, STAT1-independent activation of anti-viral and prosurvival genes (O'Donnell et al. 2012; O'Donnell et al. 2015), which might be facilitated
by access of other signaling factors — including ERK1/2 and AKT — to the activated
IFNγ receptor when STAT1 is absent or not abundant (Figure 1.3 B/C).
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Figure 1.3: The receptor-occupancy hypothesis.
In cells with abundant levels of signal transducer and activator of transcription 1 (STAT1)
signaling proteins, engagement of the interferon-γ (IFNγ) receptor (IFNGR) by its ligand
transduces a primarily STAT1-driven cellular response, leading to activation of gene
products that are chiefly antiviral (part a). By contrast, when a particular cell population
(such as hippocampal neurons) expresses reduced homeostatic levels of STAT1 (part b)
or when STAT1 is removed by genetic deletion (part c), alternative signaling molecules
with an affinity to the IFNGR may bind to this receptor, transducing unique cellular
responses. In the case of neurons, this includes activation of extracellular signalregulated kinases 1 and 2 (ERK1/2), which then can result in the induction of genes
encoding pro-survival proteins. JAK1, Janus kinase 1; KO, knockout; MEF, mouse
embryonic fibroblast. Miller KD, Schnell MJ, Rall GF. Keeping it in check: chronic viral
infection and antiviral immunity in the brain. Nature Reviews Neuroscience. November
2016:1-13.
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IFNγ is critical for the control of multiple neurotropic viral infections in both mice
and primary neuronal cultures. Recently, IFNγ was identified as a key suppressor of
HSV and VZV reactivation in the trigeminal ganglion of both humans and mice (St Leger
& Hendricks 2011; T. Liu et al. 2000; Theil et al. 2014; T. Liu et al. 2001; Kinchington et
al. 2012). What makes these studies particularly intriguing is the type of T cell shown to
be constitutively secreting IFNγ: T resident memory cells (Trm) (Theil et al. 2014; St
Leger & Hendricks 2011; T. Liu et al. 2000; T. Liu et al. 2001; T. Liu et al. 1996; Wakim
et al. 2010). Trm (defined by CD103 and CD69 expression) are in direct proximity to
latently infected PNS neurons and do not reenter circulation. Furthermore, these brainresident lymphocytes have a unique molecular signature that distinguishes them from
other types of cytotoxic T cells or from memory T cells (Wakim et al. 2012; Wakim et al.
2008). Trm populations expand and contract in their resident tissue, acting as a first line
of defense against reinfection (Park & Kupper 2015). Moreover, as suggested below,
these cells may be crucial sentinels that keep chronic neuronal infections at bay; their
loss may therefore also contribute to viral reactivation.
In addition to cytokine secretion, some T lymphocytes kill infected cells through
perforin and/or granzyme-mediated mechanisms. Perforins, found in the lytic granules of
CD8+ cytotoxic T cells, effectively punch holes in the membrane of infected target cells,
allowing for the delivery of granzymes leading to lysis of the infected cell. Granzymes
are serine proteases that induce caspase cleavage and activation of pro-apoptotic
cellular proteins, such as BID. This mode of T cell killing, which efficiently eliminates
“viral factories” has been primarily studied in rapidly dividing cells. Interestingly, in some
neuronal infections, the secretion of granzyme does not lead to lysis, but rather aids in
preventing viral reactivation and replication, while sparing the infected neuron
(Knickelbein et al. 2008). In addition to their ability to kill cells, granzymes can directly
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cleave eukaryotic translation initiation factor 4 gamma 3 (eIF4G3; a cellular protein that
is important for host and viral translation) and ICP4 (a herpesvirus-specific protein
needed for transcription of early and late viral genes) (Marcet-Palacios et al. 2011;
Knickelbein et al. 2008). By cleaving eIF4G3, granzymes thus block viral translation but
fail to induce neuronal apoptosis, further preventing viral dissemination within the host
and sparing the infected neuron. Cleavage of ICP4 by granzymes directly prevents
reactivation of latent HSV from infected neurons. In these instances, granzymes are
acting on proteins other than their traditional targets to induce an alternative neuronal
response. It has also been speculated that virus-encoded RNAs and proteins can
contribute to non-lytic outcomes. For instance, HSV LATs inhibit the action and
expression of various caspase proteins, key mediators of the cell death process. Despite
these fail-safes, bystander immune-mediated neuronal death may occur. For example,
TMEV infection of mice results in hippocampal neuron death through a mechanism that
is dependent on inflammatory monocyte infiltration and activation (Howe et al. 2012).

Humoral responses within the CNS

The notable absence of B cells in brains of virus-infected mice, coupled with noncytolytic trans-synaptic viral spread, led to the misperception that B cells and the
antibodies they secrete play minor roles in viral control. In fact, numerous human CNS
infections, including those caused by MV, PV, VZV, HSV, and flaviviruses, among
others, are characterized by the presence of intrathecal antibodies (Ab) in the CSF
(Phares, Stohlman & Bergmann 2013a; Skoldenberg et al. 1981; S et al. 1985). Humoral
responses appear to be associated with protective rather than pathogenic functions, as
seen for Japanese Encephalitis virus and some neurotropic retroviruses (Phares,
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Stohlman & Bergmann 2013a). Antibodies may be particularly beneficial for those
infections that result in extracellular infectious virus production.

V. Neuronal Subtypes and Infection
A central theme up to now has been the notion that infected cells, such as
neurons, respond to immune effectors in cell-specific ways. However, the existence of
many sub-populations of neurons, segregated by location and function, raises the issue
of whether responses may differ within these neuronal subsets. Recent studies have
shown that cerebellar granule neurons and cortical neurons pretreated with type I IFN
vary in their ability to control a WNV infection (Cho et al. 2013). Moreover, IFN treatment
had a much greater impact on the spread of infection in cerebellar granule neurons than
it did in cortical neurons (100 vs. 15 fold reduction) and this difference correlated with
discrete patterns of ISG induction (Cho et al. 2013). Animal model studies have also
shown differences in the propensity for a virus to infect individual neuronal
subpopulations and regions of the brain (Figure 1.4); for example, the hippocampus is
heavily infected by RABV, whereas MV is more often found in the midbrain (Jehmlich et
al. 2013; Liebert et al. 1986; Backzo et al. 1988; Zerboni & Arvin 2015; Lucas et al.
2015; Gomme et al. 2012). Whether these distinctions can be attributed to differences in
viral tropism or intrinsic variations in the neuronal response to soluble immune effector
proteins (or perhaps, even, how the virus gains access to the brain) is unknown.
Answering this question will require further studies that, necessarily, must integrate
virology, immunology and neurobiology.
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Figure 1.4: Tropism of neurotropic RNA viruses for distinct brain regions and neuronal
subpopulations.

The schematics show a simplified sagittal view of the mouse brain with the regions
known to be infected by various viruses indicated in red. The symbol ‘>’ indicates higher
propensity for a virus to infect a certain cell type or region of the brain than another cell
type or region. MHV, mouse hepatitis virus; MV, measles virus; RABV, rabies virus;
WNV, West Nile virus. Miller KD, Schnell MJ, Rall GF. Keeping it in check: chronic viral
infection and antiviral immunity in the brain. Nature Reviews Neuroscience. November
2016:1-13.
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VI. Measles Virus Infection of the Central Nervous System
Introduction
Before the introduction of widespread vaccination programs, according to the
World Health Organization (WHO), MV infection was responsible for approximately 2.6
million deaths each year before 1980. Despite the availability of a safe and relatively
inexpensive vaccine, there were 134,200 MV-associated deaths in 2015, with rates of
MV infection resurging due to decreases in the vaccinated public (Campbell 2016). The
majority of these fatalities occurred as a result of viral immunosuppression, leading to
opportunistic secondary infections and host death. However, CNS complications
subsequent to MV infection, as seen with the human diseases SSPE and MIBE, can
occur after uncomplicated MV infection.

Perhaps predictably, outcomes of such

sequelae are poor: SSPE is invariably fatal (Griffin et al. 2012; Gutierrez et al. 2010;
Ludlow et al. 2014; Norrby & Kristensson 1997). SSPE can present months to years
after a clinically typical MV infection, and is characterized by unrestricted MV replication
in the CNS (Griffin et al. 2012; Gutierrez et al. 2010; Ludlow et al. 2014; Norrby &
Kristensson 1997). Clear indicators predicting the development of SSPE have not yet
been identified, but age at time of infection can increase susceptibility to SSPE; children
infected with MV before 2 years of age have an increased likelihood of developing SSPE
(Gutierrez et al. 2010).
MV is a negative sense single stranded RNA virus of the genus Morbillivirus
within the family Paramyxoviridae. The timing to development of SSPE (in some cases,
as long as a decade) is surprising, as RNA viruses are not thought to persist long-term in
the CNS. The non-segmented MV genome encodes 8 proteins: 6 structural and 2 nonstructural.

The structural genes consist of the MV nucleoprotein (N), fusion (F),
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hemagglutinin (H), matrix (M), phosphoprotein (P), and the RNA-dependent RNA
polymerase (L; “large”). F, H, and M comprise the viral envelope, and P, L, and N
associate with genomic RNA to form the ribonucleoprotein (RNP) (Figure 1.5). The nonstructural MV proteins, V and C, delay apoptosis and inhibit interferon production
respectively. Many groups have long speculated that mutations in varying viral genes
(specifically, M, P, and F) result in enhanced neuropathogenesis, promoting decreased
viral budding, and increased ability to “hide” from the immune system (Millar et al. 2015;
Cattaneo et al. 1987; Haase, Swoveland, et al. 1981; E. M. Jurgens et al. 2015; Knut et
al. 1986; Liebert et al. 1986; Kweder et al. 2015). However, these studies failed to
identify consistent gene mutations amongst groups, or fully take into account the ability
of MV to switch from lytic budding to non-cytolytic trans-synaptic spread when infecting
neuronal populations.
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LARGE (polymerase)
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PHOSPHOPROTEIN
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Also:
C = inhibits IFN induction and modulates host antiviral responses
V = inhibits p73, a relative of p53, causing a delay in apoptosis

Figure 1.5: Measles virus structure and encoded genes
Cartoon depicting enveloped measles virion. Envelope associated proteins: matrix,
hemagglutinin, and fusion mediate envelope structure, receptor specificity, and host-viral
membrane fusion respectively. Ribonucleoproteins: large, nucleocapsid, and
phosphoprotein mediate viral RNA replication and genomic stability. Non-structural
proteins, V and C, delay host cell apoptosis and induction of anti-viral interferon
signaling respectively.

29

Measles virus spread in neurons of the central nervous system

The inability to recover extracellular infectious virus in brains of SSPE patients
led our laboratory to investigate the mechanism by which MV spreads in neurons. To do
so, we employed a novel transgenic mouse model, as mice are not normally permissive
to MV infection.

These transgenic mice express CD46, one of three human MV

receptors identified to date (Rall et al. 1997; Naniche et al. 1993; Dorig et al. 1993),
under the control of the neuron specific enolase promoter (NSE-CD46+ mice) (Rall et al.
1997; Naniche et al. 1993; Dorig et al. 1993). Using this model system, neurons of the
CNS can be exclusively infected, both in vivo and ex vivo.
Typically, MV infection of non-neuronal cells leads to the formation of giant multinucleated cells (syncytia; Figure 1.6). As MV proteins H and F are inserted into the lipid
bilayer of the infected host cell, these molecules can interact with receptors on adjacent
uninfected cells, inducing membrane fusion of the infected and uninfected cell.
Formation of syncytia correlates with massive amounts of detectable extracellular virus
and ultimately results in cell death by 3-4 days post infection. In contrast, and similar to
what is seen in SSPE, MV infection of primary neurons does not result in syncytia
formation, detectable extracellular virus, or cell death (Figure 1.6) (Lawrence et al.
2000). Moreover, spread of MV in primary neurons occurs in the absence of MV receptor
expression, but is dependent on cell-cell contact. Further studies by our lab have shown
that MV spread in neurons relies heavily of MV F and neurokinin-1 (NK-1), a receptor for
the neurotransmitter substance P expressed on CNS neurons. It is hypothesized that
NK-1 and F interactions possibly induce the formation of a micro-pore through which MV
genomic RNA and associated N, P, and L proteins can spread trans-synaptically in the
absence of extracellular virus release (Figure 1.7) (Makhortova et al. 2007). While this
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hypothesis remains to be tested, MV infection of neurons is non-lytic, as compared to
the highly lytic infection that occurs in non-neuronal cells.

Vero cells

NSE-CD46+ neurons

3 days post-infection
(MOI=1)

3 days post-infection
(MOI=1)

Titer = 5x105-1x106 PFU/ml

Titer = <40 PFU/ml

Extensive syncytia

No syncytia

All cells dead by 3-4 dpi

Neurons healthy
alive >10 dpi

Figure 1.6: MV spread differs among cell types.
Cells infected with MV Edmonston at an MOI=1. 72 hours post infection cells were
stained with a polyclonal MV antibody. Left: MV infected Vero cells (African monkey
kidney epithelial cells). Right: MV infected primary NSE-CD46+ neurons. Arrow indicates
synaptically connected neurons.
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Figure 1.7: Schematic for hypothetical micro-pore formation in MV infected neurons.
Neurokinin-1 (blue) and the MV fusion protein (red) interact at the synaptic junction
facilitating the fusion of pre and post-synaptic neurons, thus allowing the MV
ribonucleoprotein (green) to spread to uninfected cells without budding, and releasing
extracellular virus.

Immune mediated clearance of measles virus in the central nervous system

Trans-synaptic spread of MV could facilitate “masking” of MV from the immune
system: i.e., anti-viral antibodies in the brain parenchyma would be unable to access MV
antigens because they are entirely intracellular. However, using NSE-CD46+ mice
backcrossed to varying immune knockout backgrounds, it is clear that adaptive immune
responses—chiefly T cells-- are critical in combatting neuronal MV infection of the CNS.
Specifically, infection of NSE-CD46+/RAG2 KO adult mice, deficient in mature B
and T cells, results in 100% animal death in 3-4 weeks (Lawrence et al. 1999; Holmgren,
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Miller, Cavanaugh & Rall 2015b; Solomos et al. 2016; Cavanaugh et al. 2015; O'Donnell
et al. 2015). To further elucidate the role of individual adaptive immune cell types in
controlling MV infection, we employed combinations of immune knockout NSE-CD46+
animals and antibody mediated immune depletions. In this way we identified CD4+ T
cells as key effectors of neuronal MV control, as all infected NSE-CD46+ CD4+ T cell
depleted mice succumb to viral challenge. However, CD4+ T cells alone are insufficient
to control viral replication, as these cells need interaction with either B cells or CD8+ T
cells in order to promote animal survival, as evidenced by animal death in infected NSECD46+/B cell KO mice depleted of CD8+ T cells (Solomos et al. 2016; Tishon, Lewicki,
Andaya, McGavern, Martin & Oldstone 2006a). Aside from the role of individual immune
cell types themselves, we have identified type I and II interferons (IFNα, IFNβ, and IFNγ)
as key effectors of innate and adaptive immunity required for neuronal MV control, as a
proportion of infected animals deficient in these signaling molecules ultimately succumb
to viral challenge (Patterson, Lawrence, et al. 2002; O'Donnell et al. 2015; Cavanaugh et
al. 2015; Holmgren, Miller, Cavanaugh & Rall 2015b). Importantly, while both innate and
adaptive immune components are essential in promoting mouse survival following
neurotropic MV infection, immune-mediated viral control is noncytopathic: NSECD46+/perforin KO mice survive viral challenge, and no evidence of neuronal loss is
observed in brains of mice that controlled a MV challenge. Thus, neither the infection
nor the host response result in neuronal death, paving the way for long-term persistence
of viral RNAs in the brain, the topic of this dissertation.
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Altered neuronal immune signaling

Neuronal survival may not simply be a consequence of avoiding cell death
events, but may be due in part to induction of pro-survival proteins (Cavanaugh et al.
2015; O'Donnell et al. 2015; Rose et al. 2007; Podolsky et al. 2012). For instance,
exposure of mouse embryonic fibroblasts to type II IFN results in robust STAT activation
(phosphorylation) and downstream induction of interferon stimulated genes (ISGs), while
the same IFN exposure in neurons results in delayed kinetics of STAT activation and
induction of STAT independent ISGs (O'Donnell et al. 2015). This delayed STAT
activation and induction of alternative ISGs may steer neuronal cells away from a lytic
fate toward a pro-survival signaling profile. One such alternatively induced ISG is bone
marrow stromal antigen 2 (BST2, aka tetherin), primarily known for its ability to
physically tether budding virions to the host cell membrane (Holmgren, Miller,
Cavanaugh & Rall 2015b; Hammonds et al. 2010). BST2 is much more highly induced
upon neuronal exposure to interferon than that observed in non-neuronal MEFs (Chapter
3). However it is clear that BST2 does not play a role in restricting MV release from
neurons, its well characterized traditional role, but may actually facilitate the formation of
the micro-pore in neurons allowing MV to spread trans-synaptically (Appendix).
Conclusions
Non-cytolytic immune control, trans-synaptic spread, and differential uses of
ISGs highlight the unique outcomes in neurons when infected with MV, possibly enabling
this RNA virus to escape sterile immune mediated clearance and persist in the brain
long-term, to possibly reactivate later in life (Chapter 2). To this end, MV mRNAs have
been identified in the brains of humans who died of natural causes, in the absence of
overt clinical CNS disease, decades after an acute MV infection (Katayama et al. 1998;
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Katayama et al. 1995), making it clear that long-term MV persistence is not unique to
SSPE. Further, MV has been postulated to be an etiological trigger for a variety of CNS
and peripheral diseases, including multiple sclerosis, Alzheimers, and otosclerosis;
however, no data have yet been obtained that fulfill Koch’s postulates allowing for a
clear designation of etiology (Richard et al. 2015; B. E. Cohen et al. 2014; Kawashima et
al. 1996; Schubert 2006; Doi et al. 2016; Riddell et al. 2007; Jarius et al. 2016). In sum,
much more research will need to be conducted in order to elucidate the consequences
of long-term RNA viral persistence (Chapter 2).

VII. Emerging Principles in Neurovirology
Preservation of virus-challenged neurons from immune-mediated lysis seems
advantageous to the host, but this leaves open the possibility of long-term viral
maintenance in surviving neurons (Table 1.1). Previously, many believed that
neurotropic RNA viruses were sterilely cleared from the CNS. Indeed, unlike DNA
viruses or retroviruses, which can establish latent infections through episome formation
or integration, RNA viruses have no clear means to “survive” within a host cell. This is
especially relevant given the lability of naked RNA within the cytoplasm, which arises
due to the inherently unstable ribose subunit and the susceptibility of the 2’ hydroxyl
group to deprotonation. On the other hand, RNA viral genomes are unlikely to persist in
the cytoplasm as naked RNA; ribonucleoprotein complexes would provide some
protection and viral RNAs (like other cellular RNAs) may also be sequestered in stress
granules. Thus, mechanisms must exist to protect RNA viral genomes, allowing for their
long-term stability in the cytoplasm.
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Do these long-term infections have pathogenic potential? A set of studies from
the late 1980s showed that MV RNA can persist for decades after acute resolution in
human brains without causing neurological symptoms (Katayama et al. 1998; Nakayama
et al. 1995; Kawashima et al. 1996; Haase et al. 1985; Katayama et al. 1995); in these
studies, organs from individuals who had died of non-viral, non-CNS related causes
were screened, and a high proportion of brain tissues were found to be MV RNApositive. In addition, some have argued that MV entry into the human CNS can occur
pursuant to acute MV infection (Hanninen et al. 2014), although only a small fraction of
acutely infected persons will manifest neurological consequences. Further studies using
macaques demonstrated that MV viral RNA is detectable in peripheral tissues long after
acute infection has resolved (Lin et al. 2012). Accordingly, viral RNAs were generally
considered “fossils” that were unlikely to contribute to human disease. Surprisingly,
autopsy studies performed on brains of patients that succumbed to SSPE have shown
regions of the brain with no detectable MV proteins expressed, despite the presence of
MV RNA, suggesting that RNA, even with its inherent instability, can be maintained in a
translationally silent state (Allen et al. 1996).
The long-term persistence of viral RNA in the CNS is not unique to MV. For
example, infection of mice with MHV A59, used to study the demyelinating disease
multiple sclerosis, leads to encephalitis and hepatitis. The infectious virus is cleared from
the liver and CNS within 20 days; however the mice develop a progressive, immunemediated demyelinating disease (Matthews et al. 2001), in which viral nucleic acid
persists (Lavi et al. 1984). The potential importance of viral nucleic acid persistence in
demyelination has been subordinated by the prevailing view that long-term disease is
caused by an over-activation of the host response toward myelin proteins. Other
neurotropic RNA viruses known to persist within the mouse brain (sometimes longer
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than one year post exposure) in the absence of detectable antigen or infectious progeny
include sindbis virus (SV), Sendai virus, and RV (Koch et al. 1984; Gomme et al. 2012;
Griffin & Levine 1992). However, the lack of recoverable infectious virus does not
preclude the possibility that these viruses are actively suppressed in the CNS, similar to
the control of neuronal herpesvirus infections by Trm. Could decreases in the magnitude
or quality of the host response (for example with aging or following immunosuppressive
therapy) lead to loss of resident memory cells and reactivation of viral replication,
temporally separated from an initial infection?
The short answer is that we do not yet know. However, it was recently shown
that an endogenous retrovirus, integrated into the host genome millions of years ago,
could contribute to human neurological disease. Amyotrophic lateral sclerosis (ALS) is a
progressive neurological disease of poorly understood etiology, but consistent
inflammatory and immune mediated pathogenesis. The expression of human
endogenous retrovirus (HERV-K), specifically the envelope protein, was proposed as a
possible cause for the neuropathology seen in ALS (Li et al. 2015).
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Table 1.1: Evidence of long-term persistence of RNA viruses in CNS tissue. Miller KD,
Schnell MJ, Rall GF. Keeping it in check: chronic viral infection and antiviral immunity in
the brain. Nature Reviews Neuroscience. November 2016:1-13.
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VIII. Perspectives
Limits of detection, reproducibility, consistency in brain regions that are analyzed,
and patient-to-patient variability all contribute to the challenges and dangers of ascribing
neurotropic infections as etiologic causes of poorly understood CNS diseases.
Moreover, the association of “new” viruses with CNS disease, including the flavivirus,
Zika, and its link to microcephaly (Brasil et al. 2016; Rasmussen et al. 2016), or the
emergence of more neurovirulent influenza strains (Wiley et al. 2015) are reminders that
our understanding of the pathogenic consequences of CNS infections remains quite
primitive. Translational studies have provided insights into the links between infections
and disease, but are not without controversy. For example, the prevalence of human
cytomegalovirus (CMV) in glioblastoma has been hotly debated, though anti-CMV
treatments lead to reduction in tumor burden in some patients (Söderberg-Nauclér
2015). Furthermore, losses in host immune status due to age or chemotherapy are well
known to provoke disease, as seen with JC virus infection and progressive multifocal
leukoencephalopathy (Sudhakar et al. 2015).
Whether CNS virus infections play a larger role in human diseases of unknown
etiology remains controversial. In support of this notion, CNS neurons may be an ideal
harbor for long-term infections: nonlytic immune mechanisms spare neuronal loss while
providing an avenue for a noncytopathic virus to persist. Moreover, trans-synaptic
spread likely enables viral escape from antibody recognition or phagocytosis by antigen
presenting cells. From an evolutionary perspective, neuronal survival is paramount; thus,
sparing infected neurons a lytic fate may promote survival early on, but could potentially
open the door for viral reactivation later in life. We do not know if there are viruses that
are typically found in CNS tissues of overtly healthy individuals; with the advent of
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RNAseq technology, such studies might shed light on the potential “virome” within the
brain in both asymptomatic individuals as well as those with neurological conditions.
One final point worth noting concerns the utility of mouse models (on which many
of the studies cited in this introductory chapter were based) to study human CNS
diseases. Scientists often make the mistake of assuming that mouse survival is
equivalent to an absence of disease. This may mean that the long-term ramifications of
acute virus infections, especially those of RNA viruses that are not generally considered
life-long, may be overlooked. However, we are increasingly becoming aware that the
presence of viral fragments or latent viruses that can reactivate might evoke non-lethal
pathogenic consequences, due either to viral replication and cell damage, or to immune
responses directed against viral antigens. Such diseases, as seen with the learning
defects in LCMV-infected mice, may be subtle. Consequently, the parallel development
of more precise tools to assess CNS disease in mice, including impacts on learning,
behavior and memory, should refine how we describe neuropathogenesis in the many
valuable mouse models currently in use. Finally, determining whether or not persistent
viral nucleic acids detected within the brain are replication competent, and how these
viruses evade complete clearance (the focus of Chapter 2), could herald novel antiviral
therapies to treat or prevent devastating and prevalent human neurological and
neurodegenerative diseases (Gomme et al. 2012; Maehlen et al. 1991).
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CHAPTER 2: RNA viral persistence, reactivation, and
pathogenesis in the central nervous system

This chapter is in preparation for publication
Miller KD, O’Regan KJ, Rall GF. RNA viral persistence, reactivation, and pathogenesis
in the central nervous system. 2017
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I. Summary
It is well established that viral RNA from many neurotropic RNA viruses (e.g.,
measles virus, West Nile virus, sindbis virus, rabies virus, influenza virus) remains
detectable in the brain parenchyma long after acute infection has resolved. Moreover,
the presence of these RNAs in the absence of overt central nervous system (CNS)
disease has led many to believe that these are viral remnants with little or no potential to
reactivate. Here, we show that long-term viral persistence occurs following infection with
a neurotropic RNA virus and that viral reactivation can trigger neuropathogenesis
months after acute control. Recrudescence of viral transcription and protein synthesis
occurs after experimental depletion of adaptive immunity and is associated with a loss of
T resident memory (Trm) immune lymphocytes. Viral reactivation coincides with the onset
of severe CNS disease and motor dysfunction in mice that had presumably cleared the
infection. Viral replication and Trm are localized within the cerebellum/brain stem, and
pathogenesis associated with viral reactivation is consistent with gait and motor
problems, similar to cerebellar ataxia in humans. Our results illuminate the potential
consequences of non-lytic viral control in the CNS and demonstrate that what were once
considered “resolved” RNA viral infections can induce diseases distinct from those that
accompany acute infection.
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II. Introduction
Many CNS disorders of unknown etiology have long been speculated to have
viral triggers, such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS)
(Jarius et al. 2016; Hottenrott et al. 2017; Li et al. 2015). However, the inability to recover
infectious virus or consistently detect viral genomes in patient tissue has cast doubt on
viral etiologies for these prevalent and devastating CNS diseases. The inability to
recover infectious virus from affected brain tissues, however, does not preclude the
possibility that earlier infection may have triggered neuronal dysfunction or autoimmune
activation, ultimately resulting in disease in the absence of direct viral reproduction
(Jurgens et al. 2012; Brot et al. 1997; Gomme et al. 2012). The mechanism by which
viruses may contribute to the development of inflammatory CNS diseases is not known,
but in this report, we show that neurons of the CNS can harbor long-term persistent
infections that can reactivate and trigger neuropathology that is temporally and
phenotypically distinct from what occurs during the acute infection.
Most neurons are post-mitotic, making them a generally nonrenewable cell
population; thus, the host immune response has developed strategies to control
neurotropic infections that do not depend on neuronal lysis. The abundance of
neurotropic viruses that are controlled by the immune response in the absence of neuron
loss, including rabies virus (RV), sindbis virus (SV), measles virus (MV), West Nile virus
(WNV), herpes simplex virus (HSV), and varicella zoster virus (VZV)) (Kinchington et al.
2012; Katayama et al. 1998; Griffin 2010; Graham et al. 2016), highlights that noncytolytic immune-mediated control is a general host strategy aimed at preserving the
affected neuronal population. However, such non-lytic viral control may allow neurons to
harbor noncytopathic viruses, allowing for the incomplete eradication of viruses from the
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brain (Aronsson et al. 2002; Patterson, Lawrence, et al. 2002; Griffin & Levine 1992;
Graham et al. 2016; Kinchington et al. 2012).
The host and cellular mechanisms that govern viral persistence and reactivation
are reasonably well understood for large DNA viruses, such as HSV and VZV. For
example, recent studies using VZV and HSV have shown that cells of the adaptive
immune system are crucial for suppressing viral reactivation from latency in the CNS
and peripheral nervous system (PNS) (St Leger & Hendricks 2011; Jeon, St Leger,
Cherpes, Sheridan & Hendricks 2013b; Divito et al. 2006; Himmelein et al. 2011;
Khanna et al. 2003; T. Liu et al. 1996; T. Liu et al. 2000; Wakim et al. 2012; Theil et al.
2014; Knickelbein et al. 2008). CD8+ T cells are in direct contact with trigeminal
ganglionic neurons latently infected with HSV. Moreover, the presence of these cells
was essential to prevent reactivation of latent virus (T. Liu et al. 2000; Khanna et al.
2003; Knickelbein et al. 2008; T. Liu et al. 2001; T. Liu et al. 1996). Furthermore, these
CD8+ T cells prevented viral reactivation in a non-cytolytic manner through interferon
gamma (IFNγ), granzyme B, and lytic granule mediated mechanisms (Divito et al. 2006;
St Leger & Hendricks 2011; Jeon, St Leger, Cherpes, Sheridan & Hendricks 2013b;
Knickelbein et al. 2008). The CD8+ T cells responsible for maintenance of viral
persistence in the absence of reactivation are T resident memory (Trm) lymphocytes,
which permanently reside, expand, and contract within the immediate vicinity of latent
viral infections, distinct from memory T cells of the circulating lymph (Wakim et al. 2010;
Wakim et al. 2008; Wakim et al. 2012).
For many neurotropic viruses of both mice and humans, infectious virus cannot
be recovered from brains after the acute phase of infection, despite the presence of
detectable RNA in these tissues (Katayama et al. 1998; Katayama et al. 1995; Griffin &
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Levine 1992). This observation led many virologists to suggest that the detectable viral
RNA was a fossil, incapable of reactivation and thus having little impact on host biology.
However, it is clear that persistent RNA viral infections of the CNS can evoke
devastating host diseases as evidenced by fatal CNS diseases such as subacute
sclerosing panencephalitis (SSPE). SSPE can occur months to years after acute
infection with MV (Anlar et al. 2002), and the incidence of SSPE, once thought to occur
at a rate of 1:1700-10,000 acute MV infections, has been reevaluated based on new
data to be 1:600 in individuals infected before 1 year of age.

This re-evaluation

highlights that neuropathogenic consequences following persistence of an RNA virus
may be more common than once thought (Ludlow et al. 2014; Campbell 2016; Gutierrez
et al. 2010). Furthermore, the disease presentation following SSPE development (motor
dysfunction, cognitive defects, and ultimately death) is wholly different from that seen
during acute MV infection (maculopapular rash, fever, conjunctivitis), suggesting that the
clinical manifestations following persistence and reactivation of a previously cleared
RNA viral infection may be distinct. The long-term presence of viral (non-self) antigens in
the CNS may evoke a chronic inflammatory response, even in the absence of production
of infectious viral particles.
In this chapter of my dissertation, I demonstrate long-term persistence of MV in
the CNS of immunocompetent mice in the absence of clinical signs of CNS disease.
Viral replication in the CNS is most likely prevented by Trm and loss of these adaptive
immune cell populations in the brains of persistently infected mice results in
pathogenesis

including

gross

motor

dysfunction

(spastic

paraparesis

with

dyscoordination of the hind limbs) and weight loss. Viral persistence and reactivation
occurs in the cerebellum/brain stem regions of the CNS, resulting in symptoms similar to
cerebellar ataxia in humans. Together our data highlight the ability of an RNA virus to
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persist in neurons of the CNS and, when the host is faced with immunodeficiency, cause
disease distinct from that seen during acute infection.

III. Results
CD46 mice survive neuronal MV challenge, but fail to clear viral RNA
Our laboratory previously showed that intracranial inoculation of MV into
immunocompetent, adult NSE-CD46+ mice, in which the MV receptor CD46 is restricted
to CNS neurons, results in 100% survival with no signs of disease or weight loss at any
time point post-infection.

In contrast, immunodeficient NSE-CD46+/RAG2 KO mice

progressively lose weight and succumb to the viral challenge within 2-4 weeks postinfection, likely due to unrestricted viral replication in neurons (Figure 2.1 A/B)
(Patterson, Lawrence, et al. 2002; Lawrence et al. 1999; Rall et al. 1997; Naniche et al.
1993; Dorig et al. 1993).

Interestingly, while these mice succumb to viral infection,

careful analysis of brains from moribund NSE-CD46+/RAG2 KO mice reveals no
neuronal loss, suggesting that disease may be more attributable to neuronal dysfunction
rather than frank neuron death. In order to further characterize the possible prolonged
CNS consequences following infection of immunocompetent mice, we analyzed viral
RNA (with random hexamer priming to generate cDNA) and mRNA (with oligo dT
priming to generate cDNA) levels at varying times post infection (Figure 2.1C/D). As
expected, immunocompetent NSE-CD46+ mice controlled viral replication, reflected as
significant decreases in detectable viral RNA from 7-14 days post-infection (dpi).
Surprisingly, however, viral RNA and mRNA were still readily detected in brains long
after presumptive clearance (e.g., 90 dpi), in the absence of clinical symptoms of CNS
disease.
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Figure 2.1: NSE-CD46+ mice survive MV challenge but fail to clear viral RNA.
A. NSE-CD46+ (n=10) or NSE-CD46+/RAG-2 KO (n=5) mice were challenged i.c. with 1
x 104 pfu of MV-Edmonston and monitored daily for survival. B. Baseline weights of all
mice from (A) were obtained and compared to weights taken throughout the infection
time course. Percent weight gain or loss was then calculated. C. NSE-CD46+ mice were
challenged i.c. with 1 x 104 pfu of MV-Ed and were then sacrificed at the indicated dpi.
RNA was purified from collected brains, and subsequently analyzed by qRT-PCR (using
random hexamers to make cDNA). D. MV nucleoprotein (N) mRNA levels in NSECD46+ mice challenged i.c. with MV-Ed were detected using the approach outlined
above, substituting oligo dT primers for random hexamers to generate cDNA. Data are
represented using the ΔΔCT method. Results are representative of at least 3
independent experiments with an n>5-10 mice per group. * P< 0.05 Mann Whitney U
Test.

47

Resident memory T cells are the most abundant effector cells in the brain during
persistent infection
Recent studies using VZV and HSV have shown that cells of the adaptive
immune system (Trm) are crucial for maintaining DNA viral infections in the CNS and
PNS in a latent state (St Leger & Hendricks 2011; Jeon, St Leger, Cherpes, Sheridan &
Hendricks 2013b; Divito et al. 2006; Himmelein et al. 2011; Khanna et al. 2003; T. Liu et
al. 1996; T. Liu et al. 2000; Wakim et al. 2012; Theil et al. 2014; Knickelbein et al. 2008).
Since CD4+ T cells, CD8+ T cells, and B cells are paramount in controlling acute MV
infection of the CNS (Solomos et al. 2016; Tishon, Lewicki, Andaya, McGavern, Martin &
Oldstone 2006b) coupled with the knowledge that Trm are essential in preventing viral
reactivation of DNA viruses in neurons, we next characterized the cell populations
present in brains of mice long after viral challenge, when viral RNA can still be detected
(Tishon, Lewicki, Andaya, McGavern, Martin & Oldstone 2006a; Weidinger et al. 2001;
Weidinger et al. 2000; Lawrence et al. 1999; Reuter et al. 2012; Solomos et al. 2016).
Lymphocytes purified from whole brains of infected mice at varying time points were
subjected to flow cytometry analysis. No significant differences in the total number of B
cells, T cells, or NK cells were observed in mice that were persistently infected (data not
shown). However, a significant increase in the proportion of CD8+ T cells expressing the
resident memory markers CD103 and CD69 was detected, indicative of a Trm phenotype
(Figure 2.2A and Figure 2.3). We then confirmed that the long-term presence of these
cells in the brain is predicated on an active infection, rather than inflammation induced
during the act of intracranial viral inoculation. Indeed, Trm cells were detected after
inoculation with replicating MV; Trm were not found in either mock infected controls (PBS
IC) or animals infected with a replication incompetent MV (UV MV) (Figure 2.2B).
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Figure 2.2: CD8+ T resident memory cells are highly abundant in the CNS during
persistent infection.
A. Lymphocytes purified from whole brain tissue of perfused mice at indicated times post
infection subjected to flow cytometry analysis. Black bars: total number of CD3+/CD8+ T
cells. White: total number of CD3+/CD8+/CD103+ T cells as a proportion of total
CD3+/CD8+ T cells. n=5/group. Statistical analysis comparing the proportion of
CD103+/CD8+/CD3+ T cells during acute and persistent infection. B. Lymphocytes
purified from whole brain tissue of mock infected mice (PBS), mice inoculated with
inactivated virus (UV MV), or mice infected with replication competent MV, collected at
90dpi and subjected to FACS analysis. CD103+/CD3+/CD8+ shown as a percent of total
CD3+/CD8+ T cells. n=6/group. */# P< 0.05 Mann Whitney U Test.
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Figure 2.3: Trm express CD69.
Lymphocytes purified from whole brains of mice infected for >90 days. Percent CD69+ of
CD3+CD8+ CD103+ T cells in the brains of uninfected or persistently infected NSE-CD46+
mice. * P< 0.05 Mann Whitney U Test. N=6-18/group. Representative of at least 2
independent experiments.

The presence of Trm in the brain does not indicate that these cells have a
functional consequence; therefore, we went on to analyze the effector function of these
Trm using intracellular cytokine staining coupled with flow cytometry analysis. Coincident
with the increase in Trm during persistent infection (Figure 2.4A), levels of the effector
molecules granzyme B and interferon gamma (IFNγ) were also elevated, as compared
to the remaining CD8+ T cells in the brain (Figure 2.4B/C). Thus, Trm present during
persistent infection maintain an effector phenotype months after viral challenge.
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Figure 2.4: CD8+ Trm cells maintain an effector phenotype during persistent infection.
Lymphocytes purified from whole brains of mice infected for 7 or >90 days. A. Percent
CD3+CD8+CD103+ (Trm) of CD3+CD8+T cells in the brains of mice infected for indicated
time. B. Left – Percent IFNγ+ Trm of CD3+CD8+CD103+ T cells. Right - Percent
IFNγ+CD3+CD8+CD103- T cells. C. Left – Percent GranzymeB+Trm of CD3+CD8+CD103+
T cells. Right – Percent GranzymeB+Trm + of CD3+CD8+CD103- T cells. * P< 0.05 Mann
Whitney U Test. N=5-8/group purified CNS lymphocytes. Representative of at least 2
independent experiments.
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Transient depletion of the adaptive immune response leads to viral reactivation
This effector phenotype of Trm in the brain during persistent infection, coupled
with our observation of the critical role of adaptive immunity in controlling acute CNS
neuronal MV infection (Figure 2.1A), led us to ask whether the persistent MV RNA
observed in our model system was capable of reactivation when Trm are depleted.
Because Trm do not recirculate (Mueller & Mackay 2015), and are present within the
brains of NSE-CD46+ mice, antibody mediated depletions were not feasible due to the
restricted access of blood-borne molecules (e.g., antibodies) across the blood brain
barrier (BBB). In order to circumvent BBB restrictions and assess the role of adaptive
immunity in suppressing viral replication long-term, we used sub-lethal irradiation to
transiently deplete adaptive immune cells in persistently infected mice. After irradiation
we assessed relative amounts of detectable viral RNA and mRNA with time post
immune depletion. We observed significant increases in viral RNA and mRNA present
within the brains of persistently infected mice after immunosuppression (Figure 2.5 A/B
and Figure 2.6). Further, we began to detect expression of viral protein in the brains of
immunosuppressed mice, not seen in persistently infected immunocompent mice
(Figure 2.5C). Thus, persistent MV RNA in the brain can reactivate and synthesize viral
proteins upon transient immunosuppression.
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Figure 2.5: Sub-lethal irradiation leads to increased detection of MV RNA, mRNA, and
protein.
NSE-CD46+ mice challenged i.c. with 1x104 PFU MV-Edmonston for at least 90 days
were sub-lethally irradiated (6.5gy). RNA expression levels were determined by RTqPCR using random hexamer or oligo dT priming for cDNA generation followed by
qPCR with primers specific for the MV nucleoprotein and cyclophilin B as a standard.
Data analyzed using the ΔΔCT method. n=8-12/group from at least 2 independent
experiments. * P < 0.05 Mann Whitney U Test. A. cDNA generated using random
hexamer priming. B. cDNA generated using oligo dT priming. C. Western blot analysis of
protein purified from whole brain tissue probed for MV Fusion protein and GAPDH.
Arrow indicates MV Fusion protein.
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Figure 2.6: Sub-lethal irradiation results in increased detection of RNA for varying MV
genes.
NSE-CD46+ mice challenged i.c. with 1x104 PFU MV-Edmonston for at least 90 days
were sub-lethally irradiated (6.5gy). RNA expression levels were determined by RTqPCR using random hexamer or oligo dT priming for cDNA generation followed by
qPCR with primers specific for the MV fusion protein, hemagglutinin protein, or matrix
protein, and cyclophilin B as a standard. Data analyzed using the ΔΔCT method. n=812/group from at least 2 independent experiments. * P < 0.05 Mann Whitney U Test. AC. cDNA generated using random hexamer priming. D-F. cDNA generated using oligo
dT priming.
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Complete ablation of the adaptive immune response leads to viral reactivation and
pathogenesis
Sub-lethal irradiation only transiently depletes adaptive immune responses; thus,
reactivated virus can be re-controlled as immunity rebounds. To further investigate the
possible pathogenic outcomes of viral reactivation under conditions of permanent
immune cell loss or reduced potency, we ablated adaptive immunity in persistently
infected mice, and subsequently assessed pathogenesis in these mice. Bone marrow
chimaeras (BMCs) were established, using persistently infected mice as recipients and
bone marrow from donor immunocompetent (WT) or immunodeficient (RAG2 KO) mice.
Using this approach, we could permanently deplete the adaptive immune response from
persistently infected mice and monitor for viral reactivation and disease (Figure 2.7A
and Figure 2.8).
A proportion of reconstituted persistently infected immunodeficient (RAG2 KO)
animals displayed weight loss and kyphosis, not seen in mice reconstituted with wild
type bone marrow (Figure 2.7 B/C). Coincident with these signs of illness, mice began
to display spastic paraparesis with dyscoordination of the hind limbs (Figure 2.7C),
requiring euthanasia of ~30% of persistently infected immunodeficient recipients (Figure
2.7B). Surprisingly, analysis of whole brain tissue from immunodeficient mice
experiencing viral reactivation, compared to immunocompetent controls, did not reveal
extraordinary amounts of viral RNA (Figure 2.7D). While a clear trend towards
increasing viral RNA was observed in immunodeficient animals, detectable viral RNA
was well outside of the range observed in moribund NSE-CD46+/RAG2 KO mice (~105107 fold change of MV nucleoprotein RNA over uninfected) or mice acutely challenged
with MV 1 day post bone marrow reconstitution (Figure 2.9 A/B). Further, the
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pathogenic phenotype observed in persistently infected immunodeficient animals did not
mirror that seen in moribund NSE-CD46+/RAG2 KO animals (kyphosis, labored
breathing, and weight loss with death in ~3 weeks post infection (Figure 2.1A/B), but no
paraparesis or motor dysfunction). Thus viral RNA levels in persistently infected,
immunodeficient bone marrow recipients did not explain the observed pathogenic
phenotype.
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Figure 2.7: Ablation of the adaptive immune response after resolution of acute infection
leads to motor dysfunction and pathogenesis.
Bone marrow chimaeras were generated using NSE-CD46+ mice that had been
challenged with 1x104 PFU MV-Edmonston for >90 days. Infected mice were
reconstituted with the indicated bone marrow (WT or RAG2 KO, introduced via the retroorbital sinus) and monitored daily. A. Schematic of bone marrow chimaera generation. B.
Survival of reconstituted mice. n=14-18/group. Log-rank (Mantel-Cox) test for
significance. C. Baseline weights of all mice from (B) were obtained and compared to
weights taken throughout the reconstitution time course. Data are presented with
animals grouped into WT mice, no disease RAG2 KOs, and diseased (sick) RAG2 KOs.
n=14-18/group. D. RT-qPCR analysis of whole brain tissue collected from reconstituted
mice at indicated time post reconstitution. N=3-6/group. p values determined using the
Mann-Whitney U test. Data are representative of 2 independent experiments.
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Figure 2.8: Bone marrow chimaeras are depleted of lymphocytes in the brain.
Lymphocytes purified from whole brains of persistently infected mice or persistently
infected mice 6 weeks post bone marrow reconstitution with RAG2 KO or WT bone
marrow. A. Percent CD4+, CD8+, and CD19+ cells sorted per brain. B. Total
CD8+/CD3+/CD103+ cells/brain. C. Total CD19+ cells per brain. N=2-4 mice per group.
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Figure 2.9: Viral RNA levels in moribund animals.
NSE-CD46+ mice challenged ic with 1x104 PFU MV-Edmonston. RT-qPCR analysis of
whole brain tissue collected from indicated animals. A. NSE-CD46+/RAG2 KO animals at
indicated time post infection. B. Uninfected NSE-CD46+ mice irradiated and
reconstituted with WT or RAG2 KO bone marrow 1 day prior to infection. N=2-10/group.
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Viral persistence and reactivation occurs in the cerebellum/brain stem region of the CNS
Neurotropic viruses, including WNV and MV, show differential infectivity
throughout brain regions based on histological analysis of post-mortem brain tissue
(Hussmann et al. 2013; Cho et al. 2013; Reuter et al. 2012; Schubert 2006; Haase,
Stowring, et al. 1981; Allen et al. 1996; Omalu et al. 2003). Models of continually
replicating MV infection in the mouse CNS, as well as encephalitic models in rats, show
progression of MV through different regions of the brain over the course of infection, as
well as regions of the brain that do not become infected (Niewiesk et al. 1993; Jehmlich
et al. 2013). Furthermore, studies using WNV in mice have shown that there are basal
differences in the ability of WNV to infect cortical vs. granular neurons. Viral infection of
these distinct neuronal populations correlated with intrinsic differences in the levels of
innate immune effectors (interferon stimulated genes) expressed within these cell types
(Cho et al. 2013). A model of MV-induced encephalitis in rats also showed that
GABAergic and glutamatergic neurons were the predominant populations infected, and
that fewer cholinergic neurons, catecholaminergic neurons, astrocytes, microglia, and
endothelial cells became infected (Jehmlich et al. 2013).

These studies collectively

demonstrate inherent differences in the ability of different viruses to infect distinct
regions of the brain.
Based on these data, we decided to further explore the regional distribution of
MV during persistent infection and reactivation, with the hypothesis that MV reactivation
in a particular brain region might explain the observed pathogenic phenotype and limited
detection of viral RNA during reactivation in our BMC model. Collection of RNA from
individual brain regions and spinal cords in persistently infected mice showed a
significant increase in detectable viral RNA in the cerebellum/brain stem region when
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compared to cerebral hemispheres and spinal cords of the same animal (Figure 2.10A).
Analysis of cerebellar tissue and cerebral hemispheres obtained from persistently
infected mice 14 days post sub-lethal irradiation (14dpr) showed a significant increase in
viral replication in the cerebellum (Figure 2.10B). Further, immunohistochemical
analysis of sectioned brain tissue from persistently infected mice 14dpr revealed MV
proteins primarily in the cerebellum (Figure 2.11F), and analysis of serial sections from
persistently infected mice 14dpr showed both CD3+ and CD8+ cells entering the brain
through the 4th ventricle in direct proximity to the cerebellum, indicating that as the
immune response rebounds after irradiation, effector cells are recruited to the sites of
viral reactivation in the cerebellum (Figure 2.12 and Figure 2.13). Together, these data
show that the cerebellum/brain stem is the primary site of long-term MV persistence and
reactivation. We posit that viral reactivation in this site, the motor coordinator of the
brain, is the cause of the unique pathogenic phenotype observed with MV reactivation in
our BMC model system.
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Figure 2.10: The cerebellum is the predominant site of viral persistence and
reactivation.
A. RT-qPCR analysis of cerebellar tissue compared to cerebral hemispheres and spinal
cords collected from individual NSE-CD46+ mice infected for at least 90 days. Data are
representative of 2 independent experiments. n=6/group. B. RT-qPCR analysis of
cerebellar tissue compared to cerebral hemispheres and spinal cords collected from
individual NSE-CD46+ mice infected for at least 90 days followed by 14 days of sublethal
(6.5gy) irradiation. cDNA generated using random hexamer priming. Primers specific for
the MV nucleoprotein and cyclophillin B were used and data analyzed using the ΔΔCT
method. n=6/group. * P < 0.05 Mann Whitney U Test.
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Figure 2.11: The cerebellum is the predominant site of viral reactivation.
NSE-CD46+ mice challenged i.c. with 1x104 PFU MV-Edmonston subjected to
immunohistochemical analysis of sectioned whole brain tissue, stained with a polyclonal
MV antibody. A-C. Moribund NSE-CD46+/RAG2 KO animal. D-F. Persistently infected
NSE-CD46+ animal subjected to sub-lethal irradiation, 14 days post irradiation. Arrows
indicate positive MV staining.
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Figure 2.12: CD3+ and CD8+ cells are predominately found in the cerebellum during viral
reactivation.
Serial sections obtained from NSE-CD46+ mice challenged i.c. with 1x104 PFU MVEdmonston 90 days post infection, 14 days post sub-lethal irradiation, subjected to
immunohistochemical analysis of sectioned whole brain tissue A-C. Staining for CD3+
cells. D-F. Staining for CD8+ cells. Arrows indicate infiltrating antibody positive cells at
the 4th ventricle in the CNS.
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Figure 2.13: Trm are enriched in the cerebellum.
Lymphocytes purified from whole brains of mice infected for >90 days. Percent CD103+
of CD8+CD103+ T cells purified from cerebral hemispheres or the cerebellum of NSECD46+ mice challenged i.c. with 1x104 PFU MV-Edmonston 90 days post infection. * P<
0.05 Mann Whitney U Test. NS – not significant. N=9/group. Representative of at least 2
independent experiments.
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IV. Discussion
Before the introduction of widespread vaccination programs, MV infection was
responsible for approximately 2.6 million deaths annually, according to the World Health
Organization (WHO). Despite the availability of a safe and relatively inexpensive
vaccine, there were 134,200 MV-associated deaths in 2015, with rates of MV infection
resurging due to decreases in the vaccinated public (Campbell 2016). The majority of
these fatalities occur as a result of viral immunosuppression, leading to opportunistic
secondary infections. However, CNS complications subsequent to MV infection,
including SSPE and measles inclusion body encephalitis (MIBE), can occur after
uncomplicated MV infection.

For the majority of affected individuals, these

consequences are invariably fatal (Griffin et al. 2012; Gutierrez et al. 2010; Ludlow et al.
2014; Norrby & Kristensson 1997). SSPE can present months to years after a clinically
typical MV infection, and is characterized by unrestricted MV replication in the CNS
(Griffin et al. 2012; Gutierrez et al. 2010; Ludlow et al. 2014; Norrby & Kristensson
1997). Clear indicators predicting the development of SSPE have not yet been identified,
but age at time of infection can increase susceptibility to SSPE; children infected with
measles virus before 2 years of age have a greatly increased likelihood of developing
SSPE (Gutierrez et al. 2010). The timing to development of SSPE (in some cases, as
long as a decade) is surprising, as RNA viruses are not thought to persist long-term in
the CNS. Many groups have long speculated that mutations in varying viral genes (M, P,
and F) result in enhanced neuropathogenesis, promoting decreased viral budding, and
increased ability to “hide” from the immune system, resulting in the development of
SSPE (Millar et al. 2015; Cattaneo et al. 1987; Haase, Swoveland, et al. 1981; E. M.
Jurgens et al. 2015; Knut et al. 1986; Liebert et al. 1986; Kweder et al. 2015). However,
these studies failed to identify consistent gene mutations amongst groups, or fully take
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into account the ability of MV to switch from lytic budding to non-cytolytic trans-synaptic
spread when infecting neuronal populations.
Our findings highlight the ability of a contained, but not cleared, neuronal MV
infection to cause pathogenesis distinct from, and temporally separated from, an acute
infection. As mentioned earlier, the long-term presence of detectable viral RNA in the
CNS is not unique to MV infection; this outcome is also observed with influenza virus,
Sindbis virus, Sendai virus, West Nile virus, and rabies virus (Aronsson et al. 2002;
Griffin & Levine 1992; Koch et al. 1984; Graham et al. 2016; Gomme et al. 2012).
However, the presence of viral RNAs has not been shown to cause CNS disease or
pathology, leading many to believe that residual RNAs were remnants of the original
infection, unable to reactivate.
The fact that MV RNA persists in the CNS long-term may not be all that
surprising, as clearance and control of MV from CNS neurons is mediated in a noncytolytic fashion (Patterson, Lawrence, et al. 2002). Such non-cytolytic clearance of viral
pathogens preserves the infected neuron, while sparing the host the devastating
consequences of neuronal loss, creating a “harbor” for many viruses to persist.
However, if the immune response allows for long-term presence of non-self viral RNAs,
it must have mechanisms in place to prevent viral reactivation and the ensuing host
damage as a result of such an event.

This is especially clear in the case of HSV

infection of peripheral neurons. Latently infected trigeminal ganglion neurons are the
predominant site of HSV latency and persistence, but Trm lymphocytes, which
continuously reside next to infected neurons, keep the virus in check. These Trm secrete
interferons and lytic granules that directly prevent HSV reactivation from latency, while
maintaining the integrity of the host neuron (Wakim et al. 2010; Wakim et al. 2012; St
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Leger & Hendricks 2011; T. Liu et al. 2000; Knickelbein et al. 2008). Here, we show that
Trm are highly enriched in the MV-infected brain long after inoculation, and maintain an
effector phenotype throughout MV persistence in the CNS. Gross depletion of these
cells and adaptive immunity enables MV to reactivate within the CNS, causing disease
similar to cerebellar ataxia (gait and motor coordination abnormalities) and highlighting
the ability of adaptive immunity to control long-term subclinical infections of the CNS.
Finally, as stated previously many CNS diseases of unknown etiology have long
been speculated to have a viral trigger, but the inability to consistently detect viral
antigens or recover infectious virus from host tissue has cast doubt on such claims.
Regardless of the inability to detect viral components, in the case of MS, a positive MRZ
reaction (intrathecal antibody directed against 2 of 3 viruses; MV, rubella virus, or
varicella zoster virus) is an efficient prognostic indicator of MS (although not used
clinically), suggesting some relation to a viral infection acquired earlier in life and disease
development. Further, persistent MV infection has also been speculated as a causative
agent of otosclerosis (localized bone displacement resulting in hearing loss) (PotockaBakłażec et al. 2014; B. E. Cohen et al. 2014; Rudic et al. 2015) suggesting again that
an infection acquired earlier in life can contribute to distinct diseases that are not
typically attributed to a viral etiology. In fact, studies have identified a link between
cytomegalovirus (CMV) and glioblastoma, again suggesting a viral etiology of disease in
the CNS, as anti-CMV treatments lead to a reduction in glioblastoma tumor burden
(Söderberg-Nauclér 2015). Together, chronic non-transmissible RNA viral infections can
have severe consequences to the host. Future studies are underway to determine
exactly how adaptive immunity (most likely Trm) prevent MV reactivation over time and
determine the neuronal consequences of continued cytokine and viral exposure.
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V. Conclusion
Non-cytolytic RNA viruses, after entry into the central nervous system (CNS), can
establish long-term residence in the brain, in part due to non-cytolytic immune mediated
viral clearance. The complex architecture and distinct cell populations within the CNS
contribute to the challenging task of defining how neurotropic RNA viral infections may
alter CNS function following infection. The development of novel animal models, in
conjunction with more precise tools and technologies will greatly accelerate our
understanding of how persisting viruses can cause CNS disease long after initial
exposure. In this chapter, I have shown that an RNA viral infection can result in CNS
pathogenesis long after the acute infection has resolved. Further studies are needed
explore how the host response restricts viral replication, and how reactivation of virus
leads to a novel disease outcome.
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CHAPTER 3: BST2/Tetherin is induced in neurons by type I
interferon and viral infection but is dispensable for protection
against neurotropic viral challenge
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I. Summary
In permissive mouse central nervous system (CNS) neurons, measles virus (MV)
spreads in the absence of hallmark viral budding or neuronal death, with transmission
occurring efficiently and exclusively via the synapse. MV infection also initiates a robust
type I interferon (Ifn) response, resulting in the synthesis of a large number of genes,
including bone marrow stromal antigen-2 (Bst2)/tetherin/CD317. Bst2 restricts the
release of some enveloped viruses, but to date, its role in viral infection of neurons has
not been assessed. Consequently, we investigated how Bst2 was induced, and what
role it played in MV neuronal infection. The magnitude of induction of neuronal Bst2 RNA
and protein following Ifn exposure and viral infection was notably higher than in similarly
treated mouse embryo fibroblasts (MEFs). Bst2 synthesis was both Ifn- and Stat1dependent. Although Bst2 prevented MV release from non-neuronal cells, its deletion
had no effect on viral pathogenesis in MV-challenged mice. Our findings underscore cell
type-specific differences in Bst2 function, and its impact on viral infection and
pathogenesis.

71

II. Introduction
Many of the foundational principles in immunology have resulted from basic
observations of virus-cell interactions, including the induction and antiviral function of
both type I and type II Ifns (reviewed in (Goodbourn et al. 2000; Sorgeloos et al. 2013;
Snell & D. G. Brooks 2015)). Viral infection of a cell typically results in cellular production
and secretion of type I Ifns, which can then bind to cell surface receptors in a paracrine
and autocrine fashion, leading to synthesis of interferon stimulated genes (ISGs). These
ISGs, in turn, aid in clearing the viral infection by directly cleaving viral nucleic acids,
triggering cellular apoptosis, inducing autophagy, upregulating MHC class I expression
to aid in CD8+-mediated cytotoxicity, and preventing viral egress. Moreover, the
induction of type I Ifn contributes to the recruitment of adaptive immune effectors to
infected sites, which further promotes viral clearance.
One ISG that is highly induced following infection by many viruses, and in
response to both type I and II Ifn signaling, is bone marrow stromal antigen-2 (Bst2; also
known as HM1.24, tetherin, and CD317) (Blasius et al. 2006). Bst2 was first discovered
as a marker expressed on terminally differentiated B cells and in certain human
hematopoietic malignancies (Goto et al. 1994). The discovery that Bst2 could directly
prevent human immunodeficiency virus type 1 (HIV-1) virion release by tethering virus
particles to an infected host cell ignited interest in this novel antiviral protein. The
subsequent finding that the HIV-1 vpu protein directly antagonizes Bst2 underscored that
viruses have evolved to modulate the antiviral role of this cellular protein (Neil et al.
2008; Fitzpatrick et al. 2010; Perez-Caballero et al. 2009; Van Damme et al. 2008;
Hammonds et al. 2010). It has been shown that Bst2 can restrict budding of a variety of
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enveloped viruses including Ebola, vesicular stomatitis virus (VSV), and herpes simplex
virus (HSV)-2 (Kaletsky et al. 2009; Weidner et al. 2010; Y. Liu et al. 2015).
Bst2 is a transmembrane protein thought to directly tether the viral membrane to
the host cell membrane (reviewed in (Hotter et al. 2013; Martin-Serrano & Neil 2011;
Evans et al. 2010)). Bst2 has also been shown to activate the NF-κB pathway,
presumably further amplifying cellular stress signals (Cocka & Bates 2012). While the
functional roles of Bst2 in uninfected cells are just emerging, it is clear that many viruses
encode proteins that subvert Bst2’s antiviral activities, often by altering clathrin-mediated
endocytic pathways (Jia et al. 2014; Serra-Moreno et al. 2013; Masuyama et al. 2009).
To date, studies aimed at understanding Bst2’s role in preventing viral infection have
been limited to immune cells and rapidly dividing cell types such as fibroblasts (Sarojini
et al. 2011). Although Bst2 is induced in primary neurons following virus infection,
whether it modulates the viral life cycle in these cells has not been explored (Cho et al.
2013; O'Donnell et al. 2012).
One of our laboratory’s primary interests is to understand MV infection and
spread within CNS neurons. To do so, we use transgenic mice that express CD46, the
first identified human MV receptor, under the control of the neuron-specific enolase
promoter (NSE-CD46+ mice) (Naniche et al. 1993; Dorig et al. 1993; Rall et al. 1997).
Because mice are not normally permissive to MV infection, we can use this model to
restrict viral replication to CNS neurons. MV spread within primary neurons that are
obtained from these mice occurs through synaptic connections in the absence of
extracellular viral release, distinct from the productive and lytic infection it causes in nonneuronal cells (Makhortova et al. 2007; Lawrence et al. 2000; O'Donnell et al. 2012).
Functional clearance of MV from the CNS of NSE-CD46+ mice is noncytolytic and
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dependent on both T cells and Ifnγ (Lawrence et al. 1999; Patterson, Lawrence, et al.
2002). Interestingly, neurons differ fundamentally in the basal levels of key signaling
molecules that are required for ISG induction when compared to mouse embryonic
fibroblasts (MEFs) (Rose et al. 2007). During the course of previous studies, we
identified numerous genes that were synthesized in primary hippocampal neurons and
MEFs following Ifnγ treatment. From this list, Bst2 was among the top 5 induced genes
(O'Donnell et al. 2012). Here, we investigate the induction and contribution of Bst2 in MV
infection of CNS neurons both in vivo and ex vivo.
Using knockout mice and primary neuronal cell cultures, we show that induction
of Bst2 is dependent on Stat1 signaling induced by type I Ifn, and that Bst2 expression
can restrict MV cellular egress in a rapidly dividing, non-neuronal cell type. Moreover,
Bst2 is induced by Ifn in neurons to a much greater extent than that observed in MEFs.
Given this induction, we were surprised to find that the genetic absence of Bst2 had no
apparent effect on neuronal viral pathogenesis following infection of NSE-CD46+ mice.
Our data support a growing literature showing that neurons combat and control viral
infections in fundamentally different ways than rapidly dividing cell types.

III. Results
Bst2 is induced following interferon exposure in neurons and MEFs
In a previous study, we identified Bst2 as among the most highly induced
neuronal genes following MV infection (O'Donnell et al. 2012). To quantify this induction
more fully, we cultured primary hippocampal neurons and fibroblasts from day (d) 15
embryonic mice, as previously described (Lawrence et al. 2000; Rall et al. 1997). Five d
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post-plating, primary neurons and fibroblasts were exposed to 100 U/ml of murine
recombinant type I Ifn (Ifnβ) or type II Ifn (Ifnγ). As expected, Ifn-treated neurons and
MEFs showed a significant and rapid synthesis of Bst2 RNA relative to untreated cells
(Figure 3.1 A/B). Treatment of both neurons and MEFs with Ifnβ resulted in significantly
greater induction of Bst2 RNA than treatment with Ifnγ. Interestingly, increases in Bst2
induction were up to 50-fold greater in neurons than in MEFs.
To confirm that the changes in gene expression correlated with protein
accumulation, we examined Bst2 protein expression after Ifn treatment by western blot
and immunofluorescence microscopy. Little basal Bst2 was detected in neurons in the
absence of Ifn, but increased appreciably following Ifn exposure. No increase in protein
accumulation was observed in MEFs (Figure 3.1 C). When examining Bst2 protein
expression at the single cell level using immunofluorescence microscopy, similar results
were observed: there was an appreciable increase in detectable Bst2 protein expression
in neurons after Ifn treatment, but not MEFs (Figure 3.1 D). These data indicate that
Bst2 gene induction and protein accumulation occur in both neurons and MEFs, but that
the magnitude of induction is greater in neurons.
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Figure 3.1: Bst2 RNA and protein is induced in both primary neurons and MEFs in
response to interferon, but to a higher extent in neurons.
Primary neurons spiked with mouse recombinant type 1 interferon (Ifnβ) or type 2
interferon (Ifnγ), at a concentration of 100U/ml, were assayed for changes in Bst2 RNA
by RT-qPCR. Data are represented as fold-change compared to untreated cells using
the ΔΔCT method. N=5 per group. Unpaired T test with equal standard deviation
samples compared to 0 hour of same cell type. ** p<0.005 * p<0.05. Results of at least 3
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independent experiments are presented. Error bars represent the standard deviation
among groups. A) Bst2 RNA abundance in primary neurons. B) Bst2 RNA abundance in
primary mouse embryo fibroblasts. C) Western blot for Bst2 and Gapdh protein from
primary neurons and MEFs following Ifn exposure at a dose of 100U/ml. Image captured
using LI-COR Odyssey. D) Coverslips of primary neurons and MEFs that were spiked
with 100U/ml of Ifn for 48h or left untreated were stained for Bst2 (green), Hoescht
(blue), and β-actin (red). Each sample set is shown as Bst2 and Hoescht staining (left),
or as a merged image of Bst2, Hoescht, and β-actin (right). Primary neurons without
(top) or with (bottom) Ifn treatment (left panels). Primary MEFs without (top) or with
(bottom) Ifn treatment (right panels).

Bst2 blocks MV egress in non-neuronal cells
The observation that Bst2 is induced in response to Ifn exposure led us to assess
the role of Bst2 in limiting MV release. We infected 293T cells that had been engineered
to stably contain a tetracycline-inducible Bst2 gene, using the FLP-IN 293T-Rex system
(Invitrogen) (hereafter 293T-Bst2 cells). Bst2 is not expressed in these cells in the
absence of tetracycline (Weidner et al. 2010). 293T-Bst2 cells expressing or not
expressing Bst2 were infected with MV, and supernatants were collected at various
times post-infection and titers determined (Figure 3.2). As expected from studies of
other enveloped viruses in dividing cells, Bst2 expression resulted in a >50-fold
decrease in infectious MV released into the supernatant. This confirms that MV, like
Ebola, HIV-1, and VSV, is susceptible to Bst2-mediated restriction.
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Figure 3.2: Bst2 expression reduces MV egress in non-neuronal cells.
Supernatants were taken from MV-infected 293T-Bst2 cells with or without tetracycline
at 24, 48 and 72hpi. Results of at least 3 independent experiments are presented. Error
bars are used to indicate the standard deviation among groups. The number of
infectious virus particles released was determined by plaque assay. Data are considered
significant as determined by ANOVA. * p<0.02. N=3.

Bst2 expression is significantly induced after viral infection in primary neurons
The observation that Bst2 can limit MV release coupled with the knowledge that
Bst2 is induced more abundantly in neuronal cell populations than dividing MEFs, led us
to further explore the contribution of Bst2 in preventing MV spread and pathogenesis in
neuronal cells. For these experiments we use a transgenic mouse model in which CD46,
one of 3 identified MV receptors, and the primary receptor for vaccine strains such as
MV-Edmonston, is constitutively expressed under the transcriptional control of the
neuron specific enolase promoter (NSE-CD46+ mice), allowing for exclusively neuronal
infection (Naniche et al. 1993; Dorig et al. 1993; Rall et al. 1997). Primary hippocampal
neurons explanted from NSE-CD46+ mice were challenged with MV-Edmonston.
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Expression of Bst2 RNA was significantly elevated in MV-infected neurons, increasing
as the virus spread throughout the culture (Figure 3.3). Induction was dependent on
replicating virus, as UV-inactivated MV did not appreciably alter Bst2 expression levels.
To confirm that Bst2’s induction in response to viral infection was not unique to MV, we
infected primary neurons with lymphocytic choriomeningitis virus (LCMV), another
neurotropic, enveloped, RNA virus. Again, a significant increase in Bst2 RNA expression
was observed, correlating with time post infection (data not shown).

Figure 3.3: Viral infection induces Bst2 RNA synthesis in neurons
Primary neurons infected with MV (MOI=1) or challenged with the same dose of UVinactivated MV were assayed for Bst2 RNA levels by RT-qPCR. Data are represented as
fold-change over untreated using the ΔΔCT method. N=3 per group. Results of at least 3
independent experiments are presented. Error bars are used to indicate the standard
deviation among groups. Unpaired T test with equal standard deviation samples
compared to uninfected control. ** p<0.005 * p< 0.05.
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Bst2 induction in neurons is dependent on type I interferon signaling
To define how Bst2 is induced following MV infection, we utilized primary
hippocampal neurons obtained from several knockout mice lacking key elements of the
Ifn response pathway. When CD46+/Ifnγ knockout primary neurons were challenged with
MV, Bst2 RNA was present at similar levels to control neurons at 24 and 48 h postinfection (Figure 3.4 A). Because neurons can produce type I Ifn, we next infected
CD46+/Ifnar KO neurons (Delhaye et al. 2006), reasoning that, though these neurons
could synthesize type I Ifns in response to infection, the lack of a functional receptor
would preclude them from mounting a transcriptional response to secreted Ifns. Indeed,
the absence of a functional type I Ifn receptor ablated the virus-induced synthesis of
Bst2 at both 24 and 48 h post-infection (Figure 3.4 B). Even at 72 h post-infection,
when MV had spread extensively through the culture, as assessed by increased levels
of MV nucleoprotein RNA (Figure 3.4 C), Bst2 RNA levels remained unchanged. This
finding was further supported when primary neurons isolated from mice lacking Stat1, a
central signaling molecule in the type I Ifn cascade, were also unable to induce Bst2
during virus infection (Figure 3.4 B). From these data, we conclude that primary neurons
infected with MV synthesize Bst2 RNA through a Stat1-mediated signaling pathway
triggered by type I Ifn.
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Figure 3.4: Bst2 induction in neurons is dependent on type I Ifn signaling.
A) Primary CD46+ and CD46+/Ifnγ KO neurons were infected with MV for the indicated
times and assayed for Bst2 RNA expression by RT-qPCR. B) Primary NSE-CD46+,
NSE-CD46+/Stat1 KO, and NSE-CD46+/Ifnar KO neurons were infected with MV for the
indicated period and assayed for Bst2 RNA expression. C) Relative levels of MV
nucleoprotein RNA in indicated genotypes of primary neurons. Data represented as fold
change over uninfected using the ΔΔCT method. Results of at least 3 independent
experiments are presented. Error bars represent the standard deviation among groups.
N=3-4 per group. Unpaired T test with equal standard deviation samples compared to
uninfected control. * p< 0.05.
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Bst2 expression is induced in vivo after MV infection via type I Ifn signaling
To asses the role of type I Ifn signaling in inducing Bst2 expression in vivo, we
infected NSE-CD46+ and NSE-CD46+/Ifnar KO mice intracranially with 1x104 plaque
forming units of MV-Edmonston. All mice were monitored daily for signs of disease. At
three days post infection (dpi), animals were sacrificed and whole brains were examined
for Bst2 induction via RT-qPCR. Mice that lacked the type I Ifn receptor, and thus Ifn
signaling, were unable to induce Bst2 expression, in contrast to those with an intact Ifn
signaling pathway (Figure 3.5). These in vivo data support the results obtained from our
primary neuronal cultures and confirm type I Ifn as a critical inducer of Bst2 synthesis in
neurons after viral challenge.

Figure 3.5: Bst2 expression is induced in vivo after MV infection via type I Ifn signaling.
Mice of the indicated genotypes were infected intracranially with 1x104 PFU of the MVEdmonston. Bst2 RNA expression in whole brains was assessed 3 dpi. Data
represented as fold change over uninfected using the ΔΔCT method. N=3-4 per group.
Error bars represent the standard deviation among groups. Unpaired T test with equal
standard deviation samples compared to uninfected control. ** p<0.005.
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Bst2 is dispensable in vivo for survival after neuronal MV challenge
We hypothesized that the strong induction of Bst2 in neurons after Ifn exposure
or viral challenge, as well as the reduction in MV release from Bst2 expressing 293TBst2 cells, might imply a critical role for this molecule in maintaining neuronal health by
either contributing to an anti-viral state, or by skewing the virus toward a mechanism of
inter-neuronal spread. This was assessed following infection of various knockout mice.
Bst2 KO mice and Ifnar KO mice were backcrossed to NSE-CD46+ mice; all F2 and F3
progeny were screened for CD46 and Bst2 or Ifnar expression to ensure genotypes
(data not shown). Adults were then challenged with MV. Surprisingly, the absence of
Bst2 did not appreciably affect pathogenesis in vivo, while the absence of the type I Ifn
receptor (Ifnar), as well as its downstream signaling molecule Stat1, resulted in early
mortality after infection for approximately 10-30% of infected mice (Figure 3.6 and
(Cavanaugh et al. 2015; O'Donnell et al. 2012)). All NSE-CD46+/Bst2 KO mice survived
infection, whereas control NSE-CD46+/Rag2 KO mice, deficient in mature B and T cells,
died as a consequence of unrestricted viral spread, as previously reported (Figure 3.6
A) (Tishon, Lewicki, Andaya, McGavern, Martin & Oldstone 2006a; Patterson, Lawrence,
et al. 2002). Moreover, both NSE-CD46+ and NSE-CD46+/Bst2 KO mice maintained their
weight throughout the experiment, whereas NSE-CD46+/Rag2 KO mice progressively
wasted until they were euthanized (data not shown). Taken together, these data show
that Bst2 is significantly induced in neurons and highly dependent on type I Ifn signaling,
but is ultimately dispensable for survival after neuronal viral challenge in vivo.
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Figure 3.6: Bst2 is dispensable in vivo for survival after neuronal MV challenge.
Mice of the indicated genotypes were infected intracranially with 1x104 PFU of MVEdmonston. Percent survival with days post-infection.

IV. Discussion
Our findings underscore the importance of considering cell type specificity when
evaluating antiviral responses. While both primary neurons and fibroblasts significantly
upregulate Bst2 RNA and protein in response to viral infection and Ifn exposure, primary
mouse hippocampal neurons do so to a much greater extent. Although these neurons
have low basal expression of many ISGs, their induction is appreciable after viral
infection. The role or evolutionary advantage of lower homeostatic expression of key
signaling molecules in neurons remains to be clearly defined (Rose et al. 2007; Podolsky
et al. 2012). While the well-studied ISG, Bst2, was significantly induced in primary
neurons and in vivo, this protein appears dispensable for survival after neurotropic
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infection. Induced Bst2 expression was capable of suppressing MV release in 293T-Bst2
cells, making the lack of an effect of Bst2 following CNS viral challenge that much more
surprising.
Previous studies from our laboratory, using mice deficient in the type I Ifn
receptor, Ifnar, or its downstream signaling molecule Stat1, showed that functional type I
Ifn signaling is important for the ability to survive a neuronal MV challenge in vivo, with
>25% of mice succumbing to infection, and all surviving animals showing lasting signs of
infection and neuropathology (Cavanaugh et al. 2015; O'Donnell et al. 2012). While the
Edmonston strain of MV fully activates type I Ifn signaling during infection, as opposed to
WT strains, it is clear that loss of type I Ifn signaling results in CNS pathogenesis. The
confirmation of Bst2 as one of the most highly induced Ifn ISGs in neurons led us to
hypothesize that this gene may be a key effector in preventing MV induced death and
CNS disease, though our subsequent experiments indicated that this is not the case. It
has been previously shown that loss of Bst2 may hinder the ability of certain viruses to
gain entry to a host cell, specifically influenza virus, vesicular stomatitis virus, and
human cytomegalovirus (Viswanathan et al. 2011; Swiecki et al. 2012). Bst2 can
modulate the actin network through a Rich2 complex, maintaining microvilli integrity
(Rollason et al. 2009). As MV spreads trans-synaptically in CNS neurons, these
functions of Bst2 might help explain why Bst2 KO mice show no pathogenic
consequences after MV infection, and may implicate Bst2 as a promoter of neuronal MV
transmission (Appendix).
It is increasingly clear that neuronal viral infections are resolved by the host
immune response differently from infections of renewable cells. Although perforinmediated cell killing is a primary strategy to eliminate virus from rapidly dividing and
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renewable cell types, neurons are generally non-renewable, and thus it has been
proposed that these same cytolytic strategies may be more harmful than beneficial
within the brain. For a number of viral model systems, it has been shown that cytokinemediated, non-cytolytic strategies control many neurotropic infections (Burdeinick-Kerr et
al. 2009; Griffin 2010; Patterson, Daley, et al. 2002; Griffin & Metcalf 2011; St Leger &
Hendricks 2011; T. Liu et al. 2000; Wakim et al. 2012; Wakim et al. 2010). These data
suggest that the mechanisms by which viral infections are resolved are exquisitely cell
type-specific, and may reflect evolutionary pressures to restrict an infection while
minimizing cytopathology and tissue damage. Even more, differences among neuronal
subpopulations may further stratify the response to a viral infection, as was recently
shown for West Nile virus (Cho et al. 2013). Our studies underscore the need to
consider cell type differences when defining antiviral mechanisms; doing so may lead to
more precisely tailored therapeutic strategies to resolve life-threatening viral encephalitic
diseases.
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V. Conclusion
Viral infections of the central nervous system can lead to debilitating disease and
death. Moreover, it is becoming increasingly clear that non-renewable cells, including
most central nervous system neurons, combat neurotropic viral infections in
fundamentally different ways than other rapidly dividing and renewable cell populations.
Here we identify type I interferon signaling as a key inducer of a known anti-viral protein
(Bst2) in neurons. Unexpectedly, this gene is dispensable for clearance of neurotropic
viral infection despite its well-defined contribution to limiting the spread of enveloped
viruses in proliferating cells. A deeper appreciation of the importance of cell-type
heterogeneity in antiviral immunity will aid in the identification of unique therapeutic
targets for life-threatening viral infections.

87

CHAPTER 4: Discussion and Future Considerations
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I. Summary
Central nervous system (CNS) consequences of viral infections are rare, but
when they do occur, they are often serious and clinically challenging to manage. Our
awareness of the perils of neuroinvasion by viruses is growing: the recently appreciated
impact of Ebola and Zika virus infections on CNS integrity, decreases in vaccination
coverage for potentially neurotropic viruses such as measles, and increased
neurovirulence of some influenza strains collectively highlight the need for a better
understanding of the viral-neural interaction. Many such infections cause severe acute
disease, but the potential for neurotropic viruses to cause long-lasting damage has not
been fully explored.

In this chapter, I discuss some of the unique observations

presented in this dissertation and integrate our data with a growing literature to provide
some early insights into how CNS neurons, when faced with a viral infection that
spreads trans-synaptically, are spared from lysis, thus creating a harbor for long-term
persistence and potential pathogenic consequences later in life. At the conclusion of this
chapter, I will draw attention to an often overlooked aspect of neuropathogenesis
research: that lack of overt disease, often equated with survival post-infection, likely only
scratches the surface of the myriad ways by which neurotropic infections can impair
CNS function.
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II. Introduction
All living things, from bacteria to humans, are potential hosts for viral infections.
Though readers of this dissertation have so far survived these challenges, viral
infections are not without impact or lasting consequence. Pathogens cause a wide range
of outcomes, from short-lived inconveniences such as congestion, body aches, and
lethargy, to more serious manifestations, including diarrhea, high fever, liver cirrhosis,
and encephalitis. The identification of measles virus (MV) RNA in the CNS of
immunocompetent mice long after viral challenge was the starting point for one of the
major studies presented in this dissertation (Chapter 2), and begged the question: why
would a host allow a possibly deadly encephalitic virus to be maintained long-term?
There were a variety of directions that this project could have gone, including defining
the “state” of persisting virus, establishing how viral RNA is maintained long-term,
profiling the immunological consequences that may arise from the long-term presence of
“non-self”, and describing the host consequences when faced with viral reactivation.
Ultimately, I made the decision to understand the pathogenic consequences following
RNA viral reactivation in the brain, reasoning that such an event would illuminate both
the immunological (how is viral replication inhibited?) and virological (can maintained
viral RNA reactivate?) mechanisms of this phenomenon.
The discovery that persistent viral RNA can reactivate and lead to host
pathogenesis was intriguing, as, to date, RNA viruses are generally not thought to
persist in a replication competent state for extended periods of time. Further, the site of
viral persistence and reactivation made these findings even more exciting as they lend
credence to the hypothesis that both brain region and neuronal subtype play active roles
in dictating the course of a neuroviral infection. Defining the mechanism by which the
host immune response actively suppresses viral replication in the absence of neuronal
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cell death, and establishing the state of persisting virus in the neuronal cytoplasm will be
extremely interesting avenues to explore in the future. Further, when considering the role
of brain region and neuronal subtype, the observations presented in Chapters 3 and 4
concerning BST2 expression and function highlight the nuances that may arise in
individual cell types when faced with a viral challenge. Together, these data underscore
the need to pay closer attention to cell-type specific differences that occur after viral
infection.

III. Host Immunity Actively Suppresses Viral Replication in Neurons
without Causing Neuronal Loss
Although non-lytic viral control may allow neurons to survive an antiviral immune
assault, a consequence of such a strategy is that non-cytolytic viruses are incompletely
eradicated from the brain, as observed in NSE-CD46+ mice.

Following acute viral

control, immunocompetent MV infected mice maintain viral RNA for months to years in a
replication competent form without clinical manifestations of CNS disease (Chapter 2
and data not shown). Detection of viral RNA long after infection is not a new finding:
many viruses, including those with RNA genomes, can be maintained months after
infectious virus falls below detection limits, and in the absence of overt signs of CNS
disease (Schubert 2006; Graham et al. 2016; Griffin & Levine 1992). But for many of
these studies, it has been assumed or proposed that these RNAs are not replicationcompetent, but rather inert “fossils” marking a previous infection. We set out to test a
different hypothesis: that such long-lasting infections, while not lethal to the host, could
nevertheless impair neuronal function and host cell metabolism if reactivated (Sun et al.
2016; Gomme et al. 2012). Moreover, the CNS diseases associated with chronic viral
reactivation may not be the same as those seen in acute infection, and may in fact be
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subtler. For example, infection of neonatal mice with lymphocytic choriomeningitis virus
(LCMV) leads to a life-long infection associated with learning and memory defects (Brot
et al. 1997). In these mice, viral persistence is associated with decreased
neurotransmitter release (somatostatin) (Lipkin et al. 1988) without overt neuronal loss
or other signs of neuropathology. Thus, non-cytolytic viral control (the continued
clearance of virus from infected cells in the absence of cell death) in neurons may be
double-edged, enabling survival of crucial and generally irreplaceable cells, but providing
a haven for persistence of non-cytopathic viruses.
The plethora of neurotropic viruses that are known to be controlled in a noncytolytic manner (e.g. rabies virus, sindbis virus, measles virus, West Nile virus, herpes
simplex virus, varicella virus) (Kinchington et al. 2012; Katayama et al. 1998; Griffin
2010; Graham et al. 2016) highlights that non-cytolytic immune-mediated control is not
necessarily virus-specific, but may reflect a general host strategy to retain these crucial
and generally irreplaceable cells. Non-cytolyic immune control of viral infection is not
wholly limited to neurons within the CNS, as clearance of mouse hepatitis virus infection
from oligodendrocytes also occurs in a non-cytolytic manner (Parra et al. 1999). Thus
there appear to be conserved mechanisms that modulate or prevent immune mediated
cytotoxicity after viral infection of the CNS.
The mechanisms by which the immune response hinders viral replication while
sparing the infected cell is not clearly defined in all of examples noted above, especially
for those viruses with an RNA genome. In chapter 2, I have made the case that T
resident memory cells (Trm) are a key immune component necessary for preventing viral
reactivation within the CNS. However, it is worth noting that only approximately 50% of
T cells present in the brain during viral persistence express the hallmark Trm CD
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antigens, CD103 and CD69. This leads to the question of the function of the remaining
50% of brain CD8+ T cells: is it possible that such cells are merely “passing through” and
playing no active role in suppressing viral reactivation, or can these T cells contribute to
suppressing viral replication via a secondary or alternative mechanism?
The use of antibody-mediated immune depletions to define the functions of
individual immune cells are unlikely to be helpful in answering these questions, as their
access to the brain is restricted by the blood-brain barrier. Therefore, new mouse
models and drugs that can directly target and deplete individual cell types from both the
periphery and CNS will be required to understand the function of specific CNS-resident
immune populations during persistent infection. One approach that could be extremely
useful is the targeted expression of the diphtheria toxin receptor (DTR) on specific cell
types. In this approach, administration of diphtheria toxin (DT), which efficiently crosses
the BBB, leads to the eradication of cells expressing DTR (Reuter et al. 2012). Thus,
specific cell types could be selectively depleted if they are engineered to express DTR,
such as CD103+ or interferon gamma-expressing cells.

Using this model, one can

accurately assess the contribution of individual cell types in suppressing viral
reactivation.
While most of the studies presented in Chapter 2 focused on viral reactivation in
the absence of adaptive immunity, it is clear that innate immune signaling may also play
a critical role in the clearance and control of persisting virus, as evidenced by significant
increases in detectable viral RNA after long-term infection of NSE-CD46+/IFNAR KO
mice (data not shown). These data suggest that type I interferons may aid in controlling
persistent neuronal infection, and may account for the observed lack of 100%
penetrance in pathogenesis after viral reactivation; e.g. loss of adaptive immunity alone
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may not be wholly sufficient to lead to CNS pathogenesis following viral reactivation, as
type I and III interferons can still exert their anti-viral functions. Future studies using
persistently infected NSE-CD46+/IFNAR KO mice that are transformed, through bone
marrow chimaera strategies, to lack both adaptive immune cells and type I interferons
(NSE-CD46+/IFNAR KO/RAG2 KO mice) would be informative for the elucidation of the
role of interferons in controlling viral reactivation.
The importance of type I interferon signaling in controlling neurotropic infections
is clear, evidenced by the differential ability of West Nile virus to infect varying neuronal
populations due to differences in type I interferon signaling (varying profiles of interferon
stimulated genes (ISG) amongst sub-populations) (Cho et al. 2013). Interestingly, the
mechanisms by which interferon stimulated genes control neuronal infections may not
be identical to their traditionally described modes of action in non-neuronal cells
(Chapters 3 and 4).

Our studies with BST2 in neurons underscore this point. The

inability to detect infectious MV during neuronal infection led us to hypothesize that
BST2 may prevent MV release by tethering viral particles to the cell membrane, as
observed for other enveloped viruses in non-neuronal cells (Y. Liu et al. 2015; PerezCaballero et al. 2009). To my surprise, my analysis determined that BST2 was
dispensable for MV control in neurons (Chapter 3). Even more, further studies showed
that BST2 appears to enhance MV spread in neurons of the CNS, demonstrating a “proviral” role of this ISG (Chapter 4). Pro-viral roles of BST2 have recently been
demonstrated for other viruses, including vesicular stomatitis virus, cytomegalovirus, and
HIV (Viswanathan et al. 2011; Swiecki et al. 2012; Londrigan et al. 2015), though not in
neurons. However, the exact mechanism by which BST2 exerts pro-viral actions has yet
to be clearly defined and remains an active area of investigation. Some have speculated
that the ability of BST2 to tether emerging virions from an infected cell creates a physical
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linkage that enables a budding viral particle to maintain close proximity to adjacent
uninfected cells, perhaps facilitating cell-to-cell transfer, while preventing extracellular
viral release. Thus, BST2 may aid in “bridging the gap” between cells that are in close
proximity to one another. In the case of CNS neurons, our early data on the cellular
localization of this ISG suggests that this may not be the case, as MV spreads
predominantly via synaptic junctions and BST2 is not found in purified synaptic
preparations. Therefore, BST2 may be playing another, role other than physically
bridging the gap between synaptically connected neurons. Understanding the normal
cellular processes carried out by BST2 will be critical in better understanding its function
during viral infection.
One caveat to consider when discussing the experiments presented in this
dissertation concerns the use of primary hippocampal neurons. While primary neuronal
cultures have been vital to many of our understandings of neuronal function and
signaling, and are clearly superior to neuroblastoma cell lines that do not recapitulate
many attributes of neurons in vivo, they only offer a limited picture to the complexity of
the brain. Oligodendrocytes, astrocytes, and microglia contribute to the intricate
meshwork and communication networks essential for a fully functional neuronal network,
and their absence from a powerful but simplistic primary neuron culture may not allow a
direct correlation between in vitro cultures and viral spread and pathogenesis within the
fully intact CNS. How these interactions may contribute to ISG induction and function
has yet to be fully realized. Further, the use of hippocampal neuron cultures alone can
only offer insight into the mechanisms of viral clearance in this individual neuronal subtype. As Diamond and colleagues showed, differences among neuronal sub-populations
do exist, and thus future studies will determine if parallel pathways are being utilized in
other cellular and neuronal sub-types (Cho et al. 2013).
95

In the future, to easily and readily deduce the contributions of individual neuronal
populations, brain regions, and interferon responses during MV persistence, one can
use Gt(ROSA)26Sor lm4(ACTB-tdTomato-EGFP)luo J mice (hereafter, ROSA) (Gomme
et al. 2012). ROSA mice constitutively express tdTomato in all cells. After exposure to
Cre recombinase, the TdTomato, flanked by two loxp sites, is excised, allowing for
expression of a downstream EGFP (Muzumdar et al. 2007). We have backcrossed
ROSA mice to NSE-CD46+ mice generating NSE-CD46+/ROSA mice that allow for
neuronal infection with MV. In parallel, we have engineered a recombinant Edmonston
vaccine strain of MV expressing Cre recombinase (Cre-MV). Infection of NSECD46+/ROSA mice with Cre-MV leads to the Cre-induced irreversible change from
tdTomato expression in infected cells to EGFP expression. Thus, this system allows for
a straightforward identification of cells that have been infected with MV, via a permanent
somatic change. Providing these cells survive infection, as we know that they do (via
non-cytolytic viral control and absence of virus-mediated neuronal loss), we can now
analyze, using FACS and laser capture microdissection techniques, the unique
signatures and profiles of persistently infected neurons, as well as neurons that were
once infected but have fully resolved the infection (and are no longer viral RNA-positive).
This technique has previously allowed for the identification of neuronal impairment
following rabies virus infection of CNS neurons (Gomme et al. 2012). Together, these
studies will further define the role of adaptive and innate immunity in controlling
persistent infections in the CNS and add to the growing literature aimed at
understanding the distinctive outcomes following neurotropic infection.
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IV. Viral Promotion of Persistent Infection
The recent identification of “arbitrium” signaling (Latin for “decision” signaling) in
directing lysis-lysogeny decisions made by bacteriophage during the course of an
infection has highlighted the novel ability of viruses to communicate with their progeny
(Erez et al. 2017). In these studies, the authors demonstrate that during the course of
bacteriophage infection of Bacillus subtilis, a phage-derived small peptide fragment
(AimP) accumulates to high levels in culture medium as the bacteriophage population
surges through lytic viral replication. High concentrations of AimP can then promote its
internalization by uninfected bacterium. Upon phage infection of these AimP-carrying
bacterium, a lysogenic (vs. lytic) program is promoted via AimP’s interaction with the
phage genome and other phage-derived proteins. In sum, a peptide derived from parent
virus can “instruct” progeny virus to maintain a non-lytic lysogenic state. As levels of
AimP fall due to decreased lytic viral replication in a culture (and increased host
bacterium replication), lysogenized phage can then transition back to a lytic state and
resume producing more phage progeny. Thus, the idea that a virus is an inert replication
machine intent on producing the maximal number of infectious particles may be limited,
as viral replication appears to be far more regulated. The direct signaling of a progenitor
virus with its progeny in directing a lysogenic fate, as opposed to lytic viral life cycle in
which many thousand more progeny viruses are created, is a means by which a virus
can preserve itself in the absence of replication. While this phenomenon has thus far
been limited to bacteriophage, it is interesting to consider if parallel mechanisms could
influence the lytic to non-lytic transition seen in eukaryotic viral infections of neurons.
Aside from virally directed promotion of persistence (e.g., lysogeny, in the case of
bacteriophage, during which viral DNA is indistinguishable from host DNA) it is unlikely
that persistent viral RNAs are maintained in a naked state within a host cell. More likely,
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persistent MV RNA can directly interact with RNA binding proteins within a cell (which
are abundant in neurons) and be maintained in stress/neuronal granules (Protter &
Parker 2017). The physical architecture of neurons in which the cell body, containing the
genomic information required for survival, is highly separated by the axon from the
dynamic signaling networks seen at the synapse helps to explain the importance of RNA
granules and localized transcription seen in neurons. For a cell to respond quickly to
external stimuli (e.g. interferons and growth factors) it must be able to quickly change its
transcriptional and translation profiles. If RNAs were not readily available at the
functional synapse, a neuron would instead need to rely on transmitting external stimuli
from the synapse through the axon to the nucleus, followed by a reverse journey in
which the required transcripts and proteins then traffic back from the cell body to the
synapse to exert their function. To circumvent this time-consuming process and allow
neurons to quickly respond to localized stimuli, neurons have evolved to maintain RNAs
and translational machinery at the site of need: the synapse (Luchelli et al. 2015;
Buchan 2014; Protter & Parker 2017). Therefore, it is possible that cytoplasmic MV RNA
can be maintained and stabilized by neuronal RNA binding proteins. Alternatively, the
stability provided to MV RNA through generation of the ribonucleocapsid may enable MV
to withstand cellular RNAse activity, allowing for the long-term maintenance of viral
RNAs in the absence of binding neuronal proteins. Defining the physical state of viral
RNA during persistent infection (and where, within the neuron, the RNA is sequestered)
will be paramount to understanding how inherently labile RNA molecules are maintained
in the neuronal cytoplasm long-term, and whether viral proteins aid in directing this longterm stability.
Defective viral genomes (DVGs), or viral genomes incapable of replicating
without helper virus, have been speculated as a mode by which RNA viruses can persist
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in the absence of host clearance, as virus is not actively replicating, viral RNAs fall below
limits of detection in a host cell (Lopez 2014). DVG formation after MV infection has
been shown previously (Shingai et al. 2007). However, it has also been demonstrated
that non-defective (replication competent) MV can induce a persistent infection in
cultured cells via an auto-regulation mechanism; as high levels of the MV nucleocapsid
protein (N) accumulate within an infected cell, viral replication is slowed, presumably due
to the inability of the MV polymerase to access viral RNA tightly bound to N (Doi et al.
2016). While both the presence of MV DVGs and MV auto-regulation appear to be
plausible hypotheses to explain the ability of a cytoplasmic RNA virus to persist longterm, the latter mechanism is more likely. The hypothesis that persistent MV RNA is
maintained as a DVG, unable to replicate in the absence of helper virus, is unlikely,
considering the ability of MV to fully reactivate after long-term persistence. Identifying the
genomic sequence of persistent MV RNA will generate a better understanding as to
possible genomic mutations, or lack there of, that enable MV to persist.

V. Clinical Consequences of Viral Persistence
While the clinical manifestations of long-term RNA viral persistence have yet to
be fully realized, many CNS disorders of unknown etiology have long been speculated to
have viral triggers, such as multiple sclerosis (MS) and amyotrophic lateral sclerosis
(ALS) (Jarius et al. 2016; Hottenrott et al. 2017; Li et al. 2015). However, in many
instances, the inability to recover infectious virus or consistently detect viral genomes in
patient tissue has cast doubt on viral etiologies of these inflammatory CNS diseases.
The inability to reproducibly identify viral RNAs, proteins, or particles in host tissues may
99

be due to technical challenges (e.g., limits of detection or inconsistencies amongst
tissues sampled between groups). Regardless of the inability to detect viral components,
in the case of MS, a positive MRZ reaction (intrathecal antibody directed against 2 of 3
viruses; MV, rubella virus, or varicella zoster virus) is an efficient prognostic indicator of
MS (however, this is not used clinically), suggesting some relation to a viral infection
acquired earlier in life and disease development. Further, persistent MV infection has
also been speculated as a causative agent of otosclerosis (localized bone displacement
resulting in hearing loss) (Potocka-Bakłażec et al. 2014; B. E. Cohen et al. 2014; Rudic
et al. 2015) suggesting again that an infection acquired earlier in life can contribute to
distinct diseases that are not typically attributed to a viral etiology.
While viral genomes or infectious virus may not be consistently recovered from
these patients, it does not preclude the possibility that earlier infection may have
triggered neuronal dysfunction or autoimmune activation, ultimately resulting in disease
(H. A. Jurgens et al. 2012; Brot et al. 1997; Gomme et al. 2012). The long-term presence
of non-self antigens maintained through persistent infection, even in the absence of viral
replication, may evoke immune responses if foreign peptides are expressed at the
surface of an infected cell, long after the initial active infection has cleared. Further, the
role of antibody secreting cells (ASCs) in the promotion of clinical CNS diseases during
persistent viral infections must be considered. During mouse hepatitis virus and Theiler’s
murine encephalomyelitis virus persistent infections of the CNS, ASCs predominantly
secrete antibody directed against viral antigens, but a subset of ASCs can begin to
secrete antibodies with the ability to cross react with components of the myelin sheath
surrounding neurons, contributing to clinical CNS disease (Phares, Stohlman &
Bergmann 2013b). Regardless of the mechanism by which persistent or earlier acquired
infections contribute to CNS disease, it is clear that infections of the CNS can lead to
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sequelae different than those seen during an acute infection (Chapter 2). The ability of
persistent infection to cause disease different from that observed during the acute
infection is further evidenced when considering varicella zoster virus; initial infection
results in chicken pox while reactivation of persistent infection results in the development
of shingles (Kinchington et al. 2012). The CNS appears readily primed to harbor
persistent viral infections, due to non-cytolytic viral control as well as possible viral
mutations accumulating during replication; therefore viral causes of disease must be
reconsidered in the context of inflammatory CNS diseases of unknown etiology.

VI. The Mouse Physical Exam
While there is little doubt that murine models of neuropathogenesis have proven
extraordinarily valuable in understanding and defining how viral infections can cause
CNS disease, simply reporting outcomes in a binary way (death or survival) is likely
ignoring lessons that can be learned from these models. The 100% survival of NSECD46+ and NSE-CD46+/BST2 KO mice after MV infection clearly highlight this point, as
NSE-CD46+ mice maintain viral RNA long after initial clearance and NSE-CD46+/BST2
KO mice maintain reduced levels of viral RNA after infection (Chapters 2 and 4). Had
viral RNAs not been analyzed in these infected animals over time we would have
overlooked the subtle observations that led to the novel discoveries presented in this
dissertation; MV can persist and reactivate in the CNS long after acute infection and
BST2 enhances neuronal MV spread.
How might we better assess non-fatal consequences of neurotropic infections,
aside from simply monitoring viral loads in the brain? I propose three additions or
alterations to survival studies often used in mouse pathogenesis efforts. First, basic vital
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functions should be collected on infected mice throughout the course of infection,
including weight changes, blood pressure, temperature, and pulse oxygen saturation. A
quick Google search uncovers multiple companies that offer equipment to reliably and
quickly collect these data from mice, in some instances simultaneously. Inclusion of
these data may aid in defining dis-regulated regions of the brain during infection or
ongoing neurological disease (for example: the hypothalamus for temperature, and the
brainstem and medulla oblongata for breathing). Second, while detailed memory and
behavior tests in mice require dedicated equipment and laboratories, many motor and
cognitive tests to assess a mouse’s balance and general awareness/cognition are easily
done with limited time, expertise, and expense, even for investigators without access to
highly sophisticated tools. For example, a cylinder test can quickly identify unilateral
motor deficits. In this test, a mouse is placed into a clear cylinder and the number of
load bearing contacts the animal makes with its limbs when rearing is quantified. A
normal mouse will make an equal number of load bearing contacts with left and right
forelimbs; in contrast, favoring one limb over another may indicate damage in specific
hemispheres of the brain leading to a loss of motor control, as seen in human stroke
patients (Mani et al. 2013; S. P. Brooks & Dunnett 2009). Simple motor tests have
identified motor and rearing abnormalities associated with hippocampal dysfunction after
infection with both influenza and dengue virus (Amaral et al. 2011; H. A. Jurgens et al.
2012). Another straightforward motor phenotype analysis is to perform a footprint
analysis, in which the mouse’s front and rear paws are dipped in a dye that leaves
footprints as the mouse walks across absorbent paper. By measuring the length and
width of strides, gait disturbances can be identified and quantified (S. P. Brooks &
Dunnett 2009). Moreover, open field and grooming tests can also identify cognitive and
processing phenotypes. In the open field test, a mouse is placed into an open space
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surrounded by walls; thereafter, the time spent in center quadrants is measured. A
typical healthy mouse will immediately proceed to the wall of the field and explore
around its edges until it feels comfortable to explore more open areas.

Mice

experiencing anxiety or motor deficits will show other behaviors, which can include a
lack of movement from the open area, or a lack of curiosity about the new space (S. P.
Brooks & Dunnett 2009). Similarly, the grooming test is performed by observing a mouse
in its home cage, and quantifying the time spent grooming over a 10 minute period.
Healthy animals spend approximately 10% of their time grooming, while animals
exhibiting repetitive behaviors may spend increased time on this task (Tsai et al. 2012).
A more complete explanation of the potential benefits (and pitfalls) of using these
approaches to identify motor and cognitive defects in mouse models was published in an
excellent 2009 review by Brooks and Dunnett (S. P. Brooks & Dunnett 2009). Finally, I
propose that instead of photographs to document a particular morbidity, investigators
provide links to videos in their publications allowing the reader to have a more complete
understanding of observed disease phenotypes; the ubiquitous presence of cell phones
with high-quality video capacity makes this once-challenging task straightforward.
Certainly, many investigators have adopted strategies such as these in
evaluating cognitive or motor deficits, but most of these studies are found within the
neurobiology literature, and are less prevalent in the neurovirology/neuroimmunology
fields. I make the simple case here that such efforts could be time well spent, and could
accelerate new discoveries or deeper insights into how neurotropic viruses might impact
host biology, especially when the diseases that persisting viruses may cause are more
subtle than those observed during acute challenge.

103

VII. Conclusion
The studies presented in this dissertation add to a growing literature aimed at
elucidating cell type specific differences following viral infection. I demonstrated the
unique ability of a cytoplasmic RNA virus to persist in CNS neurons for extensive periods
(months-years) in the absence of clinical symptoms of disease, presumably as a result
of trans-synaptic viral spread and non-cytolytic immune control of viral infection. I then
showed that virus RNA replication, transcription, and protein synthesis can re-initiate and
cause host pathogenesis in response to losses of host adaptive immunity. Further,
studies aimed at understanding the role of interferon stimulated genes (ISGs) during
neurotropic viral infection highlight the ability of BST2, often characterized as an antiviral ISG, may in fact promote viral replication in primary hippocampal neurons. In sum,
this dissertation urges the reader to consider the cell type-specific differences in viral
replication, host immunity, and individual protein functions, particularly within the CNS.
Finally, in this discussion I have made the case for a more thorough “exam” of
mouse physiology after viral infection, though a reasonable counterpoint is that these
suggested ancillary tests could become time-consuming. To this point, we are reminded
of Stanley Cohen’s Nobel Prize lecture in 1986, in which he credited his discovery of
epidermal growth factor to the “side effects” of precocious eyelid opening and tooth
eruption (S. Cohen 1986). In his lecture, Cohen notes that, had he not paused to watch
his mice, this important but subtle clue would have gone unnoticed, and would have
likely postponed the paradigm-shifting discoveries that followed. Similarly, had I not
assessed MV RNA loads in apparently healthy mice long after viral inoculation, I would
have missed the novel discoveries presented in this dissertation.
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CHAPTER 5: Materials and Methods
I. Ethics Statement
These studies were carried out in accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.
The protocols were reviewed and approved by the Fox Chase Cancer Center
Institutional Animal Care and Use Committee (Office of Laboratory Animal Welfare
assurance number A3285-01).

II. Cell Culture, Interferon Treatment and Virus Infections
Primary hippocampal neurons were obtained from day 14-16 mouse embryos
and cultured in neurobasal media (Gibco) supplemented with L-glutamine in the absence
of an astrocyte feeder layer, as described previously (Rall et al. 1997; Lawrence et al.
2000; Makhortova et al. 2007). Neurons were plated on 15-mm glass coverslips or in
12-well plates coated with poly-L-lysine (Sigma-Aldrich) at a density of 2 × 105 cells/well,
unless otherwise noted. Neuron cultures were frequently quality-controlled, and were
routinely >95% Map2-positive. Neurons were plated and incubated for 5 days (d) prior to
Ifn treatment or infection to allow for full differentiation. Primary mouse embryonic
fibroblasts (MEF) were isolated from the same embryos and maintained in complete
DMEM (DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml
penicillin, and 100 ng/ml streptomycin). All cells were maintained at 37°C, 5% CO2 in a
humidified incubator. For cells treated with Ifns, recombinant murine Ifnβ or Ifnγ
(Millipore) was diluted in B27-free Neurobasal media, added to the cultures (100 U/ml
final), and incubated for the indicated times prior to collection.
MV-Edmonston (vaccine strain) was purchased from American Type Culture
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Collection and passaged and titered in Vero cells, (obtained originally from African green
monkey kidney epithelium). Passages 2 or 3 of the MV stock were used for all infections.
LCMV Armstrong (LCMV-Arm; ATCC) was passaged and plaque purified in BHK-21
cells (baby hamster kidney fibroblasts), and titers were determined on Vero fibroblasts.
All infections of primary cultures were carried out at a multiplicity of infection (MOI)=1.
Briefly, conditioned media was removed and cells were inoculated with 500µl of virus
diluted in unconditioned Neurobasal medium or DMEM for 1 hour (h) at 37°C. After
infection, cells were gently washed and conditioned medium replaced until indicated time
of harvest. 293T-Rex cells (Invitrogen) were modified to inducibly express Bst2 (293TBst2 cells) upon tetracycline exposure, (1ug/ml), and were a gift from Dr. Ju-Tao Guo
(Drexel University). These cells were maintained as described in the original report
(Weidner et al. 2010). To induce Bst2 expression, cells were treated with tetracycline for
24h, and were then infected with MV at a multiplicity of infection (MOI) of 1.0 for 1h.
Virus was then removed and replaced with fresh media, with or without tetracycline.
Synaptosome Purification
Cells were washed with cold PBS and scraped into cold 0.32M sucrose/PBS.
This was followed by slow freezing (in a Styrofoam box) at -80°C. Samples were then
thawed briefly in a 37°C water bath, followed by 30 seconds of homogenization with a
handheld motorized pestle mixer. Samples were then fractionated at 1.2xg for 20 min at
4°C. Supernatants were transferred to a new tube and spun at 12.4xg for 10 min at 4°C.
Supernatants (non-synaptic fraction) and pellets (synaptic fraction) were re-suspended
in Illustra Triple Prep kit (GE Healthcare) buffer, and then RNA and protein where
purified according to manufacturer’s instructions.
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III. RNA and Protein Analysis
Reverse transcriptase quantitative real-time PCR (RT-qPCR)
RNA was purified from whole cell lysates using the RNeasy Mini kit (Qiagen).
RNA was quantified using a Nanodrop spectrophotometer. RNA was reverse-transcribed
using High Capacity cDNA Reverse Transcription kit (Applied Biosystems) with random
hexamer priming (total RNA) or oligo dT (mRNA enriched) priming. Gene-specific
primers were used in combination with probes designed using the Universal Probe
Library algorithm (Roche) and Universal Master mix (Roche); all reactions were run on a
Mastercycler Realplex2 system (Eppendorf). Cycling conditions were 50°C, 2 min; 95°C,
10 min; followed by 40 (2-step) cycles (95°C, 15 sec; 60°C, 60 sec). Relative
quantification to the control (cyclophilin B) was done using the comparative ΔΔCT
method. Individual sample PCR reactions were performed in triplicate. The following
gene specific primers (Integrated DNA Technologies) were used: Cyclophilin B Forward
– 5’ – TTC TTC ATA ACC ACA GTC AAG ACC - 3’, Cyclophilin B Reverse – 5’ – ACC
TTC CGT ACC ACA TCC AT - 3’, UPL 20; Bst2 Forward- 5’ - GAA GTC ACG AAG CTG
AAC CA - 3’, Bst2 Reverse- 5’ – CCT GCA CTG TGC TAG AAG TCT C - 3’, UPL 78;
MV nucleoprotein Forward - 5’ – GGA AAC TGC ACC CTA CAT GG - 3’, MV
nucleoprotein Reverse- 5’ – GGG TAT GAT CCT GCA CTG AAC T - 3’, UPL 80. MV
fusion protein Forward - 5' - GAC AAA TCT GGG GAA TGC AA - 3', MV fusion protein
Reverse- 5' - GGT CCG ATG ACT CCA ACA AT - 3', UPL 88. MV matrix protein
Forward - 5' - AAT TCA GAT CGG TCA ATG CAG - 3', MV matrix protein Reverse- 5' CCT ATC GCC TTG TCA ATC CT - 3', UPL 62. MV hemagglutinin protein Forward - 5' AAA TTG GAT TAT GAT CAA TAC TGT GC - 3', MV hemagglutinin protein Reverse- 5'
- CAG TAG AGT TGA GTT CAC CAA TG - 3'', UPL 5.
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Western Blot Analysis
Whole cell lysates for western blot analysis were collected by scraping cells in 1X
protein solubilization buffer (containing SDS and EDTA) or protein was obtained from
homogenized brain tissue using TRIreagent (Sigma) as per manufacturers instructions
and stored at -80°C until analysis. Protein was run into a 10% Bis-Tris gel (Life
Technologies) in MES running buffer (Life Technologies) and transferred to an
Immobilon membrane (Millipore). Membranes were blocked with blocking buffer
(Odyssey) and immunoblotted for Gapdh (Millipore AB2302; 1:10,000), Bst2 (Sigma
PRS4661; 1:1000), human polyclonal MV (a gift from Michael B. Oldstone 1:3000), or
MV fusion protein (Bioss; 1:1000). Secondary antibodies were obtained from LI-COR
(IRDye® 680RD Donkey anti-Chicken IgG (H + L); IRDye® 800CW Donkey anti-Rabbit
IgG (H + L)). Images were captured with LI-COR Odyssey Classic Infared Imager.
Immunofluorescence
Primary neurons and MEFs were plated on coverslips and treated as previously
described. Coverslips were fixed using 4% paraformaldehyde/4% sucrose in phosphate
buffered saline, followed by further fixation and permeabilization with 100% methanol
and then with 0.2% Triton in PBS. Coverslips were blocked with 10% goat serum, 10%
fetal bovine serum in PBS. Primary antibodies for Bst2 (Sigma; 1:200) and mouse βactin (Sigma; 1:2000) were applied. Directly conjugated secondary antibodies were used
(Hoescht; 1:1000, Donkey anti-rabbit AF488; 1:5000, Goat anti-mouse AF555; 1:5000).
Coverslips were mounted to slides using Citifluor AF1 (Electron Microscopy Sciences)
and sealed. Images were captured at 40x using an inverted TE2000 Nikon C1 confocal
microscope.
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IV. In vivo Infection, Irradiation, and Reconstitution
Homozygous NSE-CD46+ transgenic mice (line 18; H-2b) (Rall et al. 1997) were
maintained in the closed breeding colony of the Fox Chase Cancer Center. Homozygous
NSE-CD46+ and haplotype-matched homozygous immune knockout (KO) mice were
intercrossed for three or more generations to obtain NSE-CD46+ mice on the desired KO
background. STAT1 KO mice were obtained from Jackson Laboratory (Meraz et al.
1996). IFNAR KO (Muller et al. 1994) mice were obtained from Luis Sigal (Fox Chase
Cancer Center, Philadelphia PA) RAG2 KO (Shinkai et al. 1992) mice were a gift from F.
W. Alt (Howard Hughes Medical Institute, Boston, Mass). The genotypes of perforin KO
(Kagi et al. 1994), IFNγ KO (Dalton et al. 1993) along with all animals used in these
studies was confirmed by PCR analysis of tail biopsy DNA.
Isoflurane-anesthetized mice were infected with MV-Edmonston via intracranial
inoculation of 1×104 PFU in a volume of 30 µl, delivered along the midline using a 27g
needle. Mice were monitored daily post-infection for signs of illness, including weight
loss, ruffled fur, ataxia, and seizures. Moribund mice were euthanized in accordance
with IACUC guidelines. RNA was isolated from individual mice at indicated times post
infection using TriReagent (Sigma) and subjected to analysis as described above.
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Irradiation and Bone Marrow Chimaeras
Sub-lethal irradiation: Mice infected for at least 90 dpi were subjected to sublethal (6.5gy) panoramic gamma irradiation using a Shepherd Model 81-14R Cs-137
panoramic irradiator. Animals were monitored daily for signs of illness until indicated
time of collection. Transient immune depletion was verified by flow cytometric analysis of
peripheral blood lymphocytes obtained from the retro-orbital sinus of isoflurane
anesthetized mice.
Bone marrow chimaera generation: Mice infected for at least 90 dpi were
subjected to lethal (2 doses of 5.5 gy separated by 4 hours) panoramic gamma
irradiation using a Shepherd Model 81-14R Cs-137 panoramic irradiator and
immediately placed onto a medicated diet (Uniprim chow). In parallel, donor animals
were euthanized and bone marrow extracted from the femur and tibia, which was then
pooled from individual donor animals and passed through a 70 µm cell strainer. Red
blood cells (RBC) were depleted using ACK lysis buffer and cells were washed twice
with sterile PBS. The isolated cells were counted using a Countess® cell counter. 10 x
106 cells were suspended in 100-200µl of PBS, and administered to irradiated recipient
mice via retro-orbital sinus 18 hours after the final irradiation of the recipients.
Reconstituted animals were observed daily for signs of illness. Depletion and
reconstitution was confirmed by flow cytometry analysis of splenic and brain
lymphocytes. Further confirmation was performed by staining stored splenic tissue from
individual animals.
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Flow cytometric analysis of purified lymphocytes
Brains and spleens were removed and pressed through a 70 µm nylon mesh cell
strainer in PBS. Dissociated tissue was run over a 70% Percoll gradient for 20 m at 4°C.
Mononuclear cells (MNCs) were recovered from the pellet, washed with PBS, treated
with 0.84% ammonium chloride to remove contaminating red blood cells (RBCs) and
washed again. Collected MNCs were counted and plated into a v-bottom 96-well plate
for subsequent antibody staining and analysis by multi-color flow cytometry. The
following antibodies (purchased from eBioscience and Biolegend) were used: APCeFluor 780 anti-mouse CD4, PE anti-mouse CD3e, PerCP-Cyanine 5.5 anti-mouse CD8,
APC anti-mouse CD103, Alexa Fluor 700 anti-mouse CD69, PE/Cy5 anti-mouse CD19,
Pacific Blue anti-mouse IFNγ, PE-Cyanine 7 anti-mouse granzyme B. Cells were
incubated with antibody for 1 h at 4°C and then washed following the incubation period.
For detection of intracellular proteins, cells were collected and stimulated
overnight with 100 ng/ml mouse recombinant IL-2 (R&D Systems) in a 37°C 5% CO2
humidified incubator, followed by 4 h of brefeldin A exposure (to plug the Golgi
apparatus) using before initial extracellular staining. After extracellular staining as
described above, cells were fixed overnight in 0.5% Paraformaldehyde, followed by
intracellular staining for 1 h at 4°C. Pelleted, stained cells were re-suspended and read
in a BD LSR II system. Percentages obtained from flow cytometry were combined with
cell counts in order to calculate total cell numbers.
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Immunohistochemistry
10 µm transverse sections were obtained from flash frozen brains (dry
ice/isopentane) in tissue embedding compound. Tissue sections were fixed with 95%
ETOH and rehydrated in PBS, followed by blocking with goat serum, avidin, and biotin
(Vector Laboratories, Burlingame California). Primary antibodies (Human polyclonal antiMV serum – a gift from Michael B. A. Oldstone; Mouse anti-CD3e – BD, Mouse antiCD8a -eBioscience) were applied for 1 h at room temperature. Secondary antibodies
(biotinylated goat anti-human HRP - Vector; biotinylated goat anti-Armenian hamster –
Santa Cruz; biotinylated goat anti-rat – Santa Cruz) were applied followed by avidinbiotin peroxidase. Antibody-positive cells were visualized using diaminobenzadine
(DAB). Tissues were counterstained using hematoxylin and mounted in an aqueous
medium. Tissue was visualized using a Nikon SMZ stereo dissecting microscope
equipped with epiflourescence optics.

V. Statistical Analysis and Figure Preparation
Data representation and statistical analysis were performed using Prism
GraphPad. Statistical analysis was performed as indicated in the figure legend. Figures
represent the results of at least 3 independent experiments, unless otherwise noted in
the figure legend. Samples were compared to an uninfected or untreated control. #/*: p<
0.05. Error bars represent the standard error of the mean.
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Appendix: Murine BST2/tetherin promotes measles virus
infection in neurons in vivo and ex vivo

This chapter is in preparation for publication
Miller KD, Matullo CM, Jones CB, Rall GF. Murine BST2/tetherin promotes measles
virus infection in neurons in vivo and ex vivo. Virology.

We gratefully acknowledge rest of the Rall lab for their contributions in discussing this
manuscript as well as our funding sources from the National Institute of Health: F31
NS092307 and T32 NS007180-32 (KDM).
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I. Summary
BST2/tetherin is an anti-viral protein induced in response to cellular exposure to
both type I and type II interferon. BST2, a transmembrane cell surface protein, is
generally considered an antiviral protein, because it can restrict the release of budding
virus particles and subsequent infection of other cells by tethering them to the host cell
membrane. We previously showed that murine BST2 is induced in primary neurons
following measles virus (MV) infection or type I interferon exposure; however, BST2 was
dispensable for protection against challenge with neuron-restricted MV. As this was the
first exploration of BST2 in neurons, we further investigated MV spread and clearance
from neurons of mice lacking BST2. Surprisingly, and in contrast to its antiviral role in
non-neuronal cells, we found that murine BST2 promotes neuronal MV spread both in
and ex vivo. BST2 is enriched in the neuronal cell body during infection and may aid in
facilitating intra-neuronal MV spread. These studies highlight a cell-type dependent role
of a well-characterized antiviral protein in enhancing neuron-specific viral infection.
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II. Introduction
Bone marrow stromal antigen 2 (BST2; also known as tetherin, HM1.24, and
CD317 (Blasius et al. 2006)) was first identified as a marker of terminally differentiated B
cells (Goto et al. 1994). Little attention was paid to this protein until the discovery that it
could prevent the release of human immunodeficiency type I (HIV-1) virus particles from
infected cells by physically tethering budding HIV-1 particles to the cell membrane (Neil
et al. 2008; Fitzpatrick et al. 2010; Perez-Caballero et al. 2009; Van Damme et al. 2008;
Hammonds et al. 2010). This finding was not limited to HIV-1; it has since been shown
that BST2 can restrict the release of many enveloped viruses, including herpes simplex
virus type 2, vesicular stomatitis virus, and Ebola virus (Y. Liu et al. 2015; Weidner et al.
2010; Kaletsky et al. 2009). The importance of BST2 in controlling viral infections is
highlighted by the fact that many viruses, including HIV-1, encode proteins that directly
antagonize BST2’s antiviral activity (Van Damme et al. 2008; Kaletsky et al. 2009).
While the contribution of BST2 in restricting viral budding continues to be
extensively studied, its role in normal cellular processes is still being defined. Currently,
it is known that BST2 is a transmembrane protein with multiple isoforms, in which
differing isoforms have alternative signaling capabilities (e.g. certain BST2 isoforms have
the ability to activate the NF-κB pathway while others can not) (Cocka & Bates 2012;
Evans et al. 2010; Hotter et al. 2013). BST2 has also been implicated in modulating
clathrin-mediated endocytosis (Cocka & Bates 2012; Martin-Serrano & Neil 2011;
Masuyama et al. 2009), and can contribute to organization of the actin cytoskeleton
(Rollason et al. 2009). Further, BST2 is induced in response to cellular type I and II
interferon (IFN) in many cell types (Blasius et al. 2006), consistent with its role in antiviral
defense. We previously showed that BST2 is highly induced in primary mouse central
nervous system (CNS) hippocampal neurons in response to both IFN exposure and MV
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infection, but was dispensable for immune-mediated control of MV in infected mice
(Holmgren, Miller, Cavanaugh & Rall 2015a; O'Donnell et al. 2012).
MV is not a natural mouse pathogen; in order to enable infection of CNS
neurons, our laboratory uses a transgenic mouse model that expresses the measles
vaccine strain receptor, CD46, under the transcriptional control of the neuron specific
enolase (NSE) promoter (NSE-CD46+ mice) (Rall et al. 1997). This allows for exclusive
infection of mouse CNS neurons with the MV-Edmonston vaccine strain (Naniche et al.
1993; Dorig et al. 1993; Rall et al. 1997). Using this model system, we have shown that
MV infection of neurons, both in and ex vivo, does not result in neuronal death
(Patterson, Lawrence, et al. 2002) and MV spread between neurons occurs in the
absence of viral budding (Makhortova et al. 2007; Lawrence et al. 2000). Thus, the
mechanism by which MV is transmitted from infected to uninfected neurons is almost
exclusively trans-synaptic. In these early studies, we provide evidence that, contrary to
its more well-defined contributions in restricting viral spread in non-neuronal cells, in
neurons, BST2 expression enhances viral replication, and its loss results in more rapid
clearance of viral RNA in vivo. Furthermore, BST2 expression is not enriched at the
synapse following MV infection of primary CD46+ neurons, suggesting that it exerts its
pro-viral role upstream of the neuronal synapse (the site of MV spread between
synaptically connected infected and uninfected neurons) (Lawrence et al. 2000;
Makhortova et al. 2007).
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III. Results
Reduced viral RNA in infected brains of mice lacking BST2
After reporting the observation that loss of BST2 had no pathogenic
consequence following neuronal MV infection (Holmgren, Miller, Cavanaugh & Rall
2015b), we next sought to determine if BST2 expression had any impact on viral
replication or spread in neurons over time. Viral RNA was therefore monitored in whole
brains of NSE-CD46+ and NSE-CD46+/BST2 KO mice throughout a two-week course.
Surprisingly, we observed a trend towards less viral RNA in the brains of NSECD46+/BST2 KO mice early during infection (Supplementary Figure S1), reaching
statistical significance by 14 dpi. These data were the first indication that BST2 may
facilitate MV replication or spread in CNS neurons in this transgenic mouse model.

Figure S1: Loss of BST2 leads to decreased detection of MV RNA in vivo.
NSE-CD46+ and NSE-CD46+/BST2 KO mice were infected intracranially with 1x104 PFU
MV-Edmonston. Whole brains were collected and analyzed for the MV nucleoprotein
RNA using RT-qPCR at 3, 7 and 14 days post infection. n = 10-12/group. Data are
represented using the ΔΔCT method. * p <0.05 Mann-Whitney U Test.
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Reduced measles virus RNA in infected BST2 deficient neurons
To further characterize the role of BST2 in neuronal MV infection, we purified
primary hippocampal neurons derived from E14 embryos of the indicated genotype,
generating primary neuronal cultures that are non-dividing and synaptically connected.
Using these cultures, we assessed the kinetics of MV replication in primary NSE-CD46+
and NSE-CD46+/BST2 KO cultures by analyzing the MV nucleoprotein RNA levels
present at varying times post infection (Supplementary Figure S2A). Similar to the
results obtained from NSE-CD46+/BST2 KO mice, primary CD46+ KO neuronal cultures
showed significantly lower viral RNA levels as compared to permissive BST2-expressing
neurons. Similar results were obtained when analyzing the amount of detectable MV
protein with time post infection (Supplementary Figure S2B). RT-qPCR and western
blot analysis revealed that NSE-CD46+/BST2 KO neurons support lower viral loads over
time.
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Figure S2: Loss of BST2 leads to decreased detection of MV ex vivo.
Primary neurons of the indicated genotype (WT: NSE-CD46+; KO: NSE-CD46+/BST2
KO) were infected with MV at an MOI=1. A) RNA was collected at the indicated time
points and analyzed by RT-qPCR for MV nucleoprotein RNA. Results of at least 6
independent experiments are represented using the ΔΔCT method. B) Western blot
analysis of protein collected at the indicated times post infection. Blots were probed with
a polyclonal MV fusion protein antibody and an antibody to GAPDH as a loading control.
A representative image is shown. * p <0.05 Wilcoxon matched pairs
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BST2 is not enriched at the synapse during neuronal MV infection
To further understand what role BST2 may be playing during trans-synaptic MV
spread, we purified synaptic and cytosolic neuronal fractions from infected NSE-CD46+
neurons at varying times post infection. Synaptic termini are purified using synaptosome
preparations, obtained following homogenization of neuronal tissue or cultures in
isotonic buffer followed by serial centrifugations.

Such preparations are enriched in

synaptosome associated protein (SNAP25) and represent sealed neuronal terminals
(Supplementary Figure S3B) (Sokolow et al. 2011). Using this established purification
technique from the neurobiology literature, we could define the cellular localization of
BST2. Our studies show that the degree of BST2 RNA expression was much greater in
the non-synaptic rather than synaptic portion of the neurons (Supplementary Figure
S3A). We further corroborated this observation to BST2 protein expression, which is
again much greater in the non-synaptic fraction of infected neurons (Supplementary
Figure S3B). These data suggest that BST2 may exert its pro-viral function upstream of
the synapse (site of MV inter-neuronal spread), of an infected neuron. Further studies
will be required to fully elucidate the mechanism by which BST2 promotes MV spread.
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Figure S3: BST2 is absent from the synapse during neuronal MV infection.
Primary NSE-CD46+ neurons were infected with MV at an MOI=1. Infected cells were
collected at the indicated time post infection followed by synaptosome purification. A)
RNA was collected at the indicated time points and analyzed by RT-qPCR for murine
BST2 (mBST2) RNA and normalized to cyclophilin B. Data represent the results of one
experiment performed in triplicate and analyzed using the ΔΔCT method. B) Western
blot analysis of protein collected at the indicated times post infection from either synaptic
or remaining (non-synaptic) fractions. Blots were probed with a polyclonal BST2
antibody or SNAP25 (to indicate synaptic fraction purity) and an antibody to GAPDH
(loading control). Data represent the results of one experiment performed in triplicate. * p
<0.05 Unpaired T test with equal standard deviations. Error bars represent SEM.
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IV. Discussion
These early data contribute to a growing literature that defines the paradoxical
roles of BST2/tetherin, perhaps explained by cell type specific differences. While the
majority of studies have focused on how this anti-viral mediator restricts release of free
virus particles, only a few studies have examined BST2 and its role in cell-cell spread of
viruses. Moreover, the potential cell-specific variation in BST2 function has not been fully
explored. It is well established that BST2 can block cellular egress of a multitude of
enveloped viral particles (Ooi et al. 2015; Holmgren, Miller, Cavanaugh & Rall 2015b; W.
Wang et al. 2015; Hammonds et al. 2010; Mahauad-Fernandez et al. 2014; Fitzpatrick et
al. 2010; Y. Liu et al. 2015; Neil et al. 2008; Sakuma et al. 2009); here, we show that
BST2 in primary hippocampal neurons contributes to trans-synaptic inter-neuronal MV
spread both in and ex vivo.
Our data contribute to a small but growing number of studies that document the
seemingly “pro-viral” functions of BST2 under some conditions. For example, in the case
of cytomegalovirus (CMV) replication, in vitro studies using primary human monocytes
and fibroblasts reveal that BST2 expression increases CMV cellular entry via a reversetethering mechanism in which BST2 expressed at the cell surface can enhance virion
binding and subsequent viral entry (Viswanathan et al. 2011). Using BST2 KO mice
infected with vesicular stomatitis virus and influenza virus similar results have been
shown (loss of BST2 results in decreased viral loads in vivo presumably due to
disruption of vesicular intracellular trafficking) (Londrigan et al. 2015; Swiecki et al.
2012).
The seemingly opposite roles of BST2 may have to do with the manner by which
the virus spreads. For example, in the case of HIV infection, BST2’s contribution in
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inhibiting spread of HIV particles has mainly focused on the release of infectious
progeny (Fitzpatrick et al. 2010; Perez-Caballero et al. 2009; Hammonds et al. 2010).
However, when investigators studied direct cell-to-cell spread of HIV-1, BST2 was found
to promote spread at the virological synapse, as knockdown of BST2 by siRNA inhibited
transmission of particles into uninfected cells (Jolly et al. 2010). Similar data were
observed with feline immunodeficiency virus (FIV): BST2 expression could efficiently
block FIV egress, but cell-to-cell transmission was enhanced, as visualized by increased
syncytia formation (Dietrich et al. 2011).
This may be of particular relevance to viral transmission in neurons: many
viruses, including MV and rabies, when infecting neurons, adopt a cell-to-cell spreading
strategy, as opposed to budding of infectious virus particles (Lawrence et al. 2000;
Makhortova et al. 2007; Gomme et al. 2012). What neuronal factors alter the viral life
cycle in this manner are not yet known. In the case of MV infection of primary
hippocampal neurons it is possible that BST2 aids in inter-neuronal MV trafficking, as
BST2 expression has been shown in the trans-Golgi network and recycling endosomes
(Masuyama et al. 2009). BST2 expression in the cytosolic neuronal trans-Golgi network
could aid in directing virus or viral protein- containing vesicles from the Golgi to the
synapse, facilitating MV spread across the synapse to an adjacent neuron. Loss of BST2
may consequently disrupt directed trafficking, leading to limited MV spread among
neurons. Alternatively, the to-date identified cellular roles of BST2, which include
clathrin-mediated endocytosis, induction of NF-κB, and impeding cellular protein
synthesis, could lead to the induction or activation of other cellular pathways necessary
to facilitate MV cell-to-cell spread (W. Wang et al. 2015; Narkpuk et al. 2014; Rollason et
al. 2009; Masuyama et al. 2009). While these are preliminary they clearly highlight the
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possible pro-viral role of BST2 after neuronal infection and underscore the need to
consider cell type-specific roles of certain ISGs.
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V. Conclusion
BST2 plays an important anti-viral role, given its ability to restrict viral budding
from infected cells. Nevertheless, its normal cellular functions have yet to be clearly
defined, and knowing the full contributions of BST2 in cell biology may inform alternative
ways by which this protein can influence viral infections. The identification that BST2 can
promote measles virus spread in neurons may help to elucidate the normal neuronal
function of BST2 in the absence of viral infection, hinting at a possible function of BST2
in directing transport of neuronal vesicles from the trans-Golgi network. It appears that
BST2 may present a possible target in preventing cell-to-cell spread of viruses; further
studies will aid in understanding how BST2 enhances cell-to-cell spread of a variety of
viruses in varying cell types.
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